Human Genetics

Jennifer Chism



First Edition, 2012

ISBN 978-81-323-3305-0

Published by:
Research World
4735/22 Prakashdeep Bldg,
Ansari Road, Darya Ganj,
Delhi - 110002
Email: info@wtbooks.com

Table of Contents

Chapter- 1

Human Genetics



A small piece of human DNA

Human genetics describes the study of inheritance as it occurs in human beings. Human genetics encompasses a variety of overlapping fields including: classical genetics, cytogenetics, molecular genetics, biochemical genetics, genomics, population genetics, developmental genetics, clinical genetics, and genetic counseling. Genes can be the common factor of the qualities of most human-inherited traits. Study of human genetics can be useful as it can answer questions about human nature, understand the diseases and development of effective disease treatment, and understand genetics of human life.

Genetic differences and inheritance patterns

Inheritance of traits for humans are based upon Gregor Mendel's model of inheritance. Mendel deduced that inheritance depends upon discrete units of inheritance, called factors or genes.

Autosomal dominant inheritance

Autosomal traits are associated with a single gene on an autosome (non-sex chromosome)—they are called "dominant" because a single copy—inherited from either parent—is enough to cause this trait to appear. This often means that one of the parents must also have the same trait, unless it has arisen due to a new mutation. Examples of autosomal dominant traits and disorders are Huntington's disease, and achondroplasia.

Autosomal recessive inheritance

Autosomal recessive traits is one pattern of inheritance for a trait, disease, or disorder to be passed on through families. For a recessive trait or disease to be displayed two copies of the trait or disorder needs to be presented. The trait or gene will be located on a non-sex chromosome. Because it takes two copies of a trait to display a trait, many people can unknowingly be carriers of a disease. From an evolutionary perspective, a recessive disease or trait can remain hidden for several generations before displaying the phenotype. Examples of autosomal recessive disorders are albinism, Cystic Fibrosis, Tay-Sachs disease.

X-linked and Y-linked inheritance

X-linked genes are found on the sex X chromosome. X-linked genes just like autosomal genes have both dominant and recessive types. Recessive X-linked disorders are rarely seen in females and usually only affect males. This is because males inherit their X chromosome and all X-linked genes will be inherited from the maternal side. Fathers only pass on their Y chromosome to their sons, so no X-linked traits will be inherited from father to son. Females express X-linked disorders when they are homozygous for the disorder and become carriers when they are heterozygous. X-linked dominant inheritance will show the same phenotype as a heterozygote and homozygote. Just like X-linked inheritance, there will be a lack of male-to-male inheritance, which makes it distinguishable from autosomal traits. One example of a X-linked trait is Coffin-Lowry syndrome, which is caused by a mutation in ribosomal protein gene. This mutation results in skeletal, craniofacial abnormalities, mental retardation, and short stature.

X chromosomes in females undergo a process known as X inactivation. X inactivation is when one of the two X chromosomes in females is almost completely inactivated. It is important that this process occurs otherwise a woman would produce twice the amount of normal X chromosome proteins. The mechanism for X inactivation will occur during the embryonic stage. For people with disorders like trisomy X, where the genotype has three X chromosomes, X-inactivation will inactivate all X chromosomes until there is only one X chromosome active. X inactivation is not only limited to females, males with Klinefelter syndrome, who have an extra X chromosome, will also undergo X inactivation to have only one completely active X chromosome.

Y-linked inheritance occurs when a gene, trait, or disorder is transferred through the Y chromosome. Since Y chromosomes can only be found in males, Y linked traits are only

passed on from father to son. The testis determining factor, which is located on the Y chromosome, determines the maleness of individuals. Besides the maleness inherited in the Y-chromosome there are no other found Y-linked characteristics.

Pedigrees



An example of a family pedigree displaying an autosomal recessive trait

A pedigree is a diagram showing the ancestral relationships and transmission of genetic traits over several generations in a family. Pedigrees are used to help detect many different genetic diseases. A pedigree can also be used to help determine the chances for a parent to produce an offspring with a specific trait. Four different traits can be identified by pedigree chart analysis: autosomal dominant, autosomal recessive, x-linked, or y-linked. Partial penetrance can be shown and calculated form pedigrees. Penetrance is the percentage expressed frequency with which individuals of a given genotype manifest at least some degree of a specific mutant phenotype associated with a trait. Inbreeding, the mating between closely related organisms of traits can clearly be seen on pedigree charts.

Pedigree charts of royal families have a high degree of inbreeding, because it was customary and preferable for royalty to marry another member of royalty. Genetic councilors commonly use pedigrees to help couple determine if the parents will be able to produce healthy children.



A karyotype of a human male, showing 46 chromosomes including XY sex chromosomes

Karyotype

A karyotype is a very useful tool in cytogenetics. A karyotype is picture of all the chromosomes in the metaphase stage arranged according to length and centromere position. A karyotype can also be useful in clinical genetics, due to its ability to diagnose genetic disorders. On a normal karyotype, aneuploidy can be detected by clearly being able to observe any missing or extra chromosomes. Giemsa banding, g-banding, of the karyotype can be used to detect deletions, insertions, duplications, inversions, and translocations. G-banding will stain the chromosomes with light and dark bands unique to each chromosome. A FISH, fluorescent in situ hybridization, can be used to observe deletions, insertions, and translocations. FISH uses fluorescent probes to bind to specific sequences of the chromosomes that will cause the chromosomes to fluoresce a unique color.

Genomics

Genomics refers to the field of genetics concerned with structural and functional studies of the genome. A genome is all the DNA contained within an organism or a cell including nuclear and mitochondrial DNA. The human genome is the total collection of genes in a human being contained in the human chromosome, composed of over three

billion nucleotides. In April 2003, the Human Genome Project was able to sequence all the DNA in the human genome, to discover the human genome was composed around 20,000 protein coding genes.

Population genetics

Population genetics is the branch of evolutionary biology responsible for investigating processes that cause changes in allele and genotype frequencies in populations based upon Mendelian inheritance. Four different forces can influence the frequencies: natural selection, mutation, gene flow (migration), and genetic drift. A population can be defined as a group of interbreeding individuals and their offspring. For human genetics the populations will consist only of the human species. The Hardy-Weinberg principle is a widely used principle to determine allelic and genotype frequencies.

Hardy-Weinberg principle

The Hardy-Weinberg principle states that when no evolution occurs in a population the allele and genotype frequencies do not change from one generation to the next. No evolution refers to no mutation, no gene flow, no natural selection, and no genetic drift. To be in equilibrium two more assumptions need to be made that random mating occurs and there are discrete, non-overlapping generations.

Mitochondrial DNA

In addition to nuclear DNA, humans (like almost all eukaryotes) have mitochondrial DNA. Mitochondria, the "power houses" of a cell, have their own DNA because they are descended from a proteobacterium that merged with eukaryotic cells over 2 billion years ago—an assertion known as the endosymbiotic hypothesis. Mitochondria are inherited from one's mother, and its DNA is frequently used to trace maternal lines of descent. Mitochondrial DNA is only 16kb in length and encodes for 62 genes.

Genes and human characteristics

Genes are a fundamental unit of inheritance. Genes can be defined as a sequence of DNA in the genome that is required for production of a functional product. Genes have both minor and major effects on human characteristics. Human genes have become prominent in the nature versus nurture debate.

Genes and behavior

Genes have a strong influence on human behavior. IQ is largely heritable. However, this has been questioned. The stance that humans inherit substantial behavioral characteristics is called psychological nativism, compared to the stance that human behavior and culture are virtually entirely constructed (tabula rasa).

In the early 20th century, eugenics was policy in parts of the United States and Europe. The goal was to reduce or eliminate traits that were considered undesirable. One form of eugenics was compulsory sterilization of people deemed mentally unfit. Hitler's eugenics programs turned social consciousness against the practice, and psychological nativism became associated with racism and sexism.

Evolutionary psychology

Evolutionary psychology explains many human behaviors as more or less moderated by genes that evolved in the hunter-gatherer stage of human cultural development.

Genetic disorders

Humans have several genetic diseases, often blamed on rare recessive genes. A few examples of human genetic diseases are: Turner Syndrome, Huntington's disease, Downs Syndrome (in some cases), and sickle cell anemia.

- Cri du Chat syndrome – A disorder caused from a deletion on the short arm of chromosome 5. This deletion results in a phenotype of mental retardation, behavioral problems, and a cat like call. About one in every 50,000 births will have the syndrome.
- Huntington's disease – A neurological disorder caused by a trinucleotide repeat sequence. Huntingtons is an autosomal dominant trait. Most individuals with the disease will first display the phenotype around 40 years of age. The symptoms are jerky uncontrollable movements, mental retardation, and behavioral problems.
- Turner syndrome – A condition that affects females caused by a 45, XO genotype instead of the normal XX genotype. These individuals have only one X chromosome. These individuals are phenotypically female, but will be sterile due to undeveloped ovaries.
- Klinefelter syndrome – A disorder in males caused by the presence of an extra X chromosome. These individuals have a genotype of 47, XXY instead of the normal XY genotype. The symptoms for this syndrome are enlarged breasts, small testes, and sterility.

Human traits with simple inheritance patterns

Dominant	Recessive
Widow's peak	No Widow's peak
Facial Dimples	No Facial Dimples
Able to taste PTC	Unable to taste PTC
Unattached earlobe	Attached earlobe
Cleft chin	No Cleft chin
Brunette iris (anatomy)	Blue Iris (anatomy)
Color Vision	Color blindness

Brown Hair	Blonde Hair
normal	turned up nose
Ability to roll tongue (Able to hold tongue in a U shape)	No ability to roll tongue
Normal Pinkies	Crooked Pinkies
Normal Thumb	Hitchhiker's Thumb
Freckles	No Freckles
Wet-type earwax	Dry-type earwax
Curly Hair	Straight Hair

Chapter- 2

Human Genome



A graphical representation of the normal human karyotype

The **human genome** is the genome of *Homo sapiens*, which is stored on 23 chromosome pairs. 22 of these are autosomal chromosome pairs, while the remaining pair is sex-determining. The haploid human genome occupies a total of just over 3 billion DNA base pairs. The Human Genome Project (HGP) produced a reference sequence of the euchromatic human genome, which is used worldwide in biomedical sciences.

The haploid human genome contains ca. 23,000 protein-coding genes, far fewer than had been expected before its sequencing. In fact, only about 1.5% of the genome codes for proteins, while the rest consists of non-coding RNA genes, regulatory sequences, introns, and noncoding DNA (once known as "junk DNA").

Features

Genes

There are estimated to be between 20,000 and 25,000 human protein-coding genes. The estimate of the number of human genes has been repeatedly revised down as genome sequence quality and gene finding methods have improved. Earlier predictions estimated that human cells have as much as 200,000 genes.

Surprisingly, the number of human genes seems to be less than a factor of two greater than that of many much simpler organisms, such as the roundworm and the fruit fly. However, human cells make extensive use of alternative splicing to produce several different proteins from a single gene, and the human proteome is thought to be much larger than those of the aforementioned organisms. Besides, most human genes have multiple exons, and human introns are frequently much longer than the flanking exons.

Human genes are distributed unevenly across the chromosomes. Each chromosome contains various gene-rich and gene-poor regions, which seem to be correlated with chromosome bands and GC-content. The significance of these nonrandom patterns of gene density is not well understood. In addition to protein coding genes, the human genome contains thousands of RNA genes, including tRNA, ribosomal RNA, microRNA, and other non-coding RNA genes.

Regulatory sequences

The human genome has many different regulatory sequences which are crucial to controlling gene expression. These are typically short sequences that appear near or within genes. A systematic understanding of these regulatory sequences and how they together act as a gene regulatory network is only beginning to emerge from computational, high-throughput expression and comparative genomics studies. Some types of non-coding DNA are genetic "switches" that do not encode proteins, but do regulate when and where genes are expressed.

Identification of regulatory sequences relies in part on evolutionary conservation. The evolutionary branch between the primates and mouse, for example, occurred 70–90

million years ago. So computer comparisons of gene sequences that identify conserved non-coding sequences will be an indication of their importance in duties such as gene regulation.

Another comparative genomic approach to locating regulatory sequences in humans is the gene sequencing of the puffer fish. These vertebrates have essentially the same genes and regulatory gene sequences as humans, but with only one-eighth the noncoding DNA. The compact DNA sequence of the puffer fish makes it much easier to locate the regulatory genes.

Other DNA

Protein-coding sequences (specifically, coding exons) comprise less than 1.5% of the human genome. Aside from genes and known regulatory sequences, the human genome contains vast regions of DNA the function of which, if any, remains unknown. These regions in fact comprise the vast majority, by some estimates 97%, of the human genome size. Much of this is composed of:

Repeat elements

- Tandem repeats
  - Satellite DNA
  - Minisatellite
  - Microsatellite
- Interspersed repeats
  - SINEs
  - LINEs

Transposons

- Retrotransposons
  - LTR
    - Ty1-copia
    - Ty3-gypsy
  - Non-LTR
    - SINEs
    - LINEs
- DNA Transposons

Noncoding DNA

There is also a large amount of sequence that does not fall under any known classification. Much of this sequence may be an evolutionary artifact that serves no present-day purpose, and these regions are collectively referred to as noncoding DNA. These regions were once referred to as "junk" DNA; however, there are a variety of emerging indications that many sequences within are likely to function in ways that are

not fully understood. Recent experiments using microarrays have revealed that a substantial fraction of non-genic DNA is in fact transcribed into RNA, which leads to the possibility that the resulting transcripts may have some unknown function. Also, the evolutionary conservation across the mammalian genomes of much more sequence than can be explained by protein-coding regions indicates that many, and perhaps most, functional elements in the genome remain unknown. The investigation of the vast quantity of sequence information in the human genome whose function remains unknown is currently a major avenue of scientific inquiry. Meanwhile, considering the global genome DNA information as a whole could provide new ways to understand a possible global level function of non coding DNA.

Information content

The 2.9 billion base pairs of the haploid human genome correspond to a maximum of about 691.4 megabytes of data, since every base pair can be coded by 2 bits. However, due to the high degree of redundancy of the human genome, it can be losslessly compressed to roughly 4 megabytes.

The entropy rate of the genome differs significantly between coding and non-coding sequences. It is close to the maximum of 2 bits per base pair for the coding sequences (about 45 million base pairs), but less for the non-coding parts. It ranges between 1.5 and 1.9 bits per base pair for the individual chromosome, except for the Y chromosome, which has an entropy rate below 0.9 bits per base pair.

Sequencing

DNA sequencing determines the order of the nucleotide bases in a genome.

Composite

The Human Genome Project and a parallel project by Celera Genomics each produced and published a haploid human genome sequence, both of which were a composite of the DNA sequence of several individuals.

Personal

A personal genome sequence is a complete sequencing of the chemical base pairs that make up the DNA of a single person. Because medical treatments have different effects on different people because of genetic variations such as single-nucleotide polymorphisms (SNPs), the analysis of personal genomes may lead to personalized medical treatment based on individual genotypes.

The completion of the fifth such map was announced in December 2008. The genome mapped was that of a Korean researcher Seong-Jin Kim. Genome maps had previously been completed for Craig Venter of the U.S. in 2007, James Watson of the U.S. in April

2008, and Yang Huanming of China in November 2008 and Dan Stoicescu in January 2008.

Personal genomes had not been sequenced in the Human Genome Project to protect the identity of volunteers who provided DNA samples. That sequence was derived from the DNA of several volunteers from a diverse population. Another distinction is that the HGP sequence is haploid, however, the sequence maps for Venter and Watson for example are diploid, representing both sets of chromosomes.

Kim's genome had 1.58 million SNPs that had never been reported before and indicates that six out of 10,000 DNA bases are unique to Koreans. Kim's sequence map can be used to assist in building a standard Korean genome, which can then be used to compare the genomes of other Korean individuals for personalized medical treatments.

Mapping

Whereas a genome sequence lists the order of every DNA base in a genome, a genome map identifies the landmarks. A genome map is less detailed than a genome sequence and aids in navigating around the genome.

Variation

An example of a variation map is the HapMap being developed by the International HapMap Project. The HapMap is a haplotype map of the human genome, "which will describe the common patterns of human DNA sequence variation." It catalogs the patterns of small-scale variations in the genome that involve single DNA letters, or bases.

Researchers published the first sequence-based map of large-scale structural variation across the human genome in the journal *Nature* in May 2008. Large-scale structural variations are differences in the genome among people that range from a few thousand to a few million DNA bases; some are gains or losses of stretches of genome sequence and others appear as re-arrangements of stretches of sequence. These variations include differences in the number of copies individuals have of a particular gene, deletions, translocations and inversions.

Variation

Most studies of human genetic variation have focused on single-nucleotide polymorphisms (SNPs), which are substitutions in individual bases along a chromosome. Most analyses estimate that SNPs occur on average somewhere between every 1 in 100 and 1 in 300 base pairs in the euchromatic human genome, although they do not occur at a uniform density. Thus follows the popular statement that "we are all, regardless of race, genetically 99.9% the same", although this would be somewhat qualified by most geneticists. For example, a much larger fraction of the genome is now thought to be involved in copy number variation. A large-scale collaborative effort to catalog SNP

variations in the human genome is being undertaken by the International HapMap Project.

The genomic loci and length of certain types of small repetitive sequences are highly variable from person to person, which is the basis of DNA fingerprinting and DNA paternity testing technologies. The heterochromatic portions of the human genome, which total several hundred million base pairs, are also thought to be quite variable within the human population (they are so repetitive and so long that they cannot be accurately sequenced with current technology). These regions contain few genes, and it is unclear whether any significant phenotypic effect results from typical variation in repeats or heterochromatin.

Most gross genomic mutations in gamete germ cells probably result in inviable embryos; however, a number of human diseases are related to large-scale genomic abnormalities. Down syndrome, Turner Syndrome, and a number of other diseases result from nondisjunction of entire chromosomes. Cancer cells frequently have aneuploidy of chromosomes and chromosome arms, although a cause and effect relationship between aneuploidy and cancer has not been established.

Genetic disorders

Most aspects of human biology involve both genetic (inherited) and non-genetic (environmental) factors. Some inherited variation influences aspects of our biology that are not medical in nature (height, eye color, ability to taste or smell certain compounds, etc.). Moreover, some genetic disorders only cause disease in combination with the appropriate environmental factors (such as diet). With these caveats, genetic disorders may be described as clinically defined diseases caused by genomic DNA sequence variation. In the most straightforward cases, the disorder can be associated with variation in a single gene. For example, cystic fibrosis is caused by mutations in the CFTR gene, and is the most common recessive disorder in caucasian populations with over 1,300 different mutations known. Disease-causing mutations in specific genes are usually severe in terms of gene function, and are fortunately rare, thus genetic disorders are similarly individually rare. However, since there are many genes that can vary to cause genetic disorders, in aggregate they comprise a significant component of known medical conditions, especially in pediatric medicine. Molecularly characterized genetic disorders are those for which the underlying causal gene has been identified, currently there are approximately 2,200 such disorders annotated in the OMIM database.

Studies of genetic disorders are often performed by means of family-based studies. In some instances population based approaches are employed, particularly in the case of so-called founder populations such as those in Finland, French-Canada, Utah, Sardinia, etc. Diagnosis and treatment of genetic disorders are usually performed by a geneticist-physician trained in clinical/medical genetics. The results of the Human Genome Project are likely to provide increased availability of genetic testing for gene-related disorders, and eventually improved treatment. Parents can be screened for hereditary conditions and

counselled on the consequences, the probability it will be inherited, and how to avoid or ameliorate it in their offspring.

As noted above, there are many different kinds of DNA sequence variation, ranging from complete extra or missing chromosomes down to single nucleotide changes. It is generally presumed that much naturally occurring genetic variation in human populations is phenotypically neutral, i.e. has little or no detectable effect on the physiology of the individual (although there may be fractional differences in fitness defined over evolutionary time frames). Genetic disorders can be caused by any or all known types of sequence variation. To molecularly characterize a new genetic disorder, it is necessary to establish a causal link between a particular genomic sequence variant and the clinical disease under investigation. Such studies constitute the realm of human molecular genetics.

With the advent of the Human Genome and International HapMap Project, it has become feasible to explore subtle genetic influences on many common disease conditions such as diabetes, asthma, migraine, schizophrenia, etc. Although some causal links have been made between genomic sequence variants in particular genes and some of these diseases, often with much publicity in the general media, these are usually not considered to be genetic disorders *per se* as their causes are complex, involving many different genetic and environmental factors. Thus there may be disagreement in particular cases whether a specific medical condition should be termed a genetic disorder.

Evolution

Comparative genomics studies of mammalian genomes suggest that approximately 5% of the human genome has been conserved by evolution since the divergence of extant lineages approximately 200 million years ago, containing the vast majority of genes. Intriguingly, since genes and known regulatory sequences probably comprise less than 2% of the genome, this suggests that there may be more unknown functional sequence than known functional sequence. A smaller, yet substantial, fraction of human genes seem to be shared among most known vertebrates. The published chimpanzee genome differs from that of the human genome by 1.23% in direct sequence comparisons. Around 20% of this figure is accounted for by variation within each species, leaving only ~1.06% consistent sequence divergence between humans and chimps at shared genes. This nucleotide by nucleotide difference is dwarfed, however, by the portion of each genome that is not shared, including around 6% of functional genes that are unique to either humans or chimps. In other words, the considerable observable differences between humans and chimps may be due as much or more to genome level variation in the number, function and expression of genes rather than DNA sequence changes in shared genes. On average, a typical human protein-coding gene differs from its chimpanzee ortholog by only two amino acid substitutions; nearly one third of human genes have exactly the same protein translation as their chimpanzee orthologs. A major difference between the two genomes is human chromosome 2, which is equivalent to a fusion product of chimpanzee chromosomes 12 and 13 (later renamed to chromosomes 2A and 2B, respectively).

Humans have undergone an extraordinary loss of olfactory receptor genes during our recent evolution, which explains our relatively crude sense of smell compared to most other mammals. Evolutionary evidence suggests that the emergence of color vision in humans and several other primate species has diminished the need for the sense of smell.

Mitochondrial genome

The human mitochondrial genome, while usually not included when referring to the "human genome", is of tremendous interest to geneticists, since it undoubtedly plays a role in mitochondrial disease. It also sheds light on human evolution; for example, analysis of variation in the human mitochondrial genome has led to the postulation of a recent common ancestor for all humans on the maternal line of descent.

Due to the lack of a system for checking for copying errors, Mitochondrial DNA (mtDNA) has a more rapid rate of variation than nuclear DNA. This 20-fold increase in the mutation rate allows mtDNA to be used for more accurate tracing of maternal ancestry. Studies of mtDNA in populations have allowed ancient migration paths to be traced, such as the migration of Native Americans from Siberia or Polynesians from southeastern Asia. It has also been used to show that there is no trace of Neanderthal DNA in the European gene mixture inherited through purely maternal lineage.

Epigenome

Epigenetics are a variety of features of the human genome that transcend its primary DNA sequence, such as chromatin packaging, histone modifications and DNA methylation, and which are important in regulating gene expression, genome replication and other cellular processes. Epigenetic markers strengthen and weaken transcription of certain genes but do not affect the actual sequence of DNA nucleotides.

Chapter- 3

Human Evolutionary Genetics

Human evolutionary genetics studies how one human genome differs from the other, the evolutionary past that gave rise to it, and its current effects. Differences between genomes have anthropological, medical and forensic implications and applications. Genetic data can provide important insight into human evolution.

Origin of apes



Taxonomic relationships of hominoids

Biologists classify humans, along with only a few other species, as great apes (species in the family Hominidae). The Hominidae include two distinct species of chimpanzee (the bonobo, *Pan paniscus*, and the common chimpanzee, *Pan troglodytes*), two species of gorilla (the western gorilla, *Gorilla gorilla*, and the eastern gorilla, *Gorilla graueri*), and two species of orangutan (the Bornean orangutan, *Pongo pygmaeus*, and the Sumatran orangutan, *Pongo abelii*).

Apes, in turn, belong to the primates order (>400 species). Data from both mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) indicates that primates belong to the group of Euarchontoglires, together with Rodentia, Lagomorpha, Dermoptera, and Scandentia. This is further supported by Alu-like short interspersed nuclear elements (SINEs) which have been found only in members of the Euarchontoglires.

Cladistics



A phylogenetic tree like the one shown above is usually derived from DNA or protein sequences from populations. Often mitochondrial DNA or Y chromosome sequences are used to study ancient human demographics. These single-locus sources of DNA do not recombine and are almost always inherited from a single parent, with only one known exception in mtDNA (Schwartz and Vissing 2002). Individuals from the various continental groups tend to be more similar to one another than to people from other continents. The tree is rooted in the common ancestor of chimpanzees and humans, which is believed to have originated in Africa. Horizontal distance in the diagram corresponds to two things:

1. **Genetic distance**. Given below the diagram, the genetic difference between humans and chimps is less than 2%, or 20 times larger than the variation among modern humans.
2. **Temporal remoteness** of the most recent common ancestor. Rough estimates are given above the diagram, in millions of years. The mitochondrial most recent common ancestor of modern humans lived roughly 200,000 years ago, latest common ancestors of humans and chimps between four and seven million years ago.

Chimpanzees and humans belong to different genera, indicated in red. Formation of species and subspecies is also indicated, and the formation of "races" is indicated in the green rectangle to the right (note that only a very rough representation of human phylogeny is given). Note that vertical distances are not meaningful in this representation.

Speciation of humans and the African apes

The separation of humans from their closest relatives, the African apes (chimpanzees and gorillas), has been studied extensively for more than a century. Five major questions have been addressed:

- Which apes are our closest ancestors?
- When did the separations occur?
- What was the effective population size of the common ancestor before the split?
- Are there traces of population structure (subpopulations) preceding the speciation or partial admixture succeeding it?
- What were the specific events (including fusion of chromosomes 2a and 2b) prior to and subsequent to the separation?

General observations

As discussed before, different parts of the genome show different sequence divergence between different hominoids. It has also been shown that the sequence divergence between DNA from humans and chimpanzees varies greatly. For example the sequence divergence varies between 0% to 2.66% between non-coding, non-repetitive genomic regions of humans and chimpanzees. Additionally gene trees, generated by comparative analysis of DNA segments, do not always fit the species tree. Summing up:

- The sequence divergence varies significantly between humans, chimpanzees and gorillas.
- For most DNA sequences, humans and chimpanzees appear to be most closely related, but some point to a human-gorilla or chimpanzee-gorilla clade.
- The human genome has been sequenced, as well as the chimpanzee genome. Humans have 23 pairs of chromosomes, while chimpanzees, gorillas, and orangutans have 24. Human chromosome 2 is a fusion between two chromosomes that remained separate in the other primates.

Divergence times

The divergence time of humans from other apes is of great interest. One of the first molecular studies, published in 1967 measured immunological distances (IDs) between different primates. Basically the study measured the strength of immunological response that an antigen from one species (human albumin) induces in the immune system of another species (human, chimpanzee, gorilla and Old World monkeys). Closely related species should have similar antigens and therefore weaker immunological response to each other's antigens. The immunological response of a species to its own antigens (e.g. human to human) was set to be 1. The ID between humans and gorillas was determined to be 1.09, that between humans and chimpanzees was determined as 1.14. However the distance to six different Old World monkeys was on average 2.46 indicating that the African apes are far closer related to humans than to monkeys. The authors consider the divergence time between Old World monkeys and hominoids to be 30 million years ago (MYA), based on fossil data, and the immunological distance was considered to grow at a constant rate. They concluded that divergence time of humans and the African apes to be roughly ~5 MYA. That was a surprising result. Most scientists at that time thought that humans and great apes diverged much earlier (>15 MYA). The gorilla was, in ID terms, closer to human than to chimpanzees, however the difference was so slight that the trichotomy could not be resolved with certainty. Later studies based on molecular genetics were able to resolve the trichotomy: chimpanzees are phylogenetically closer to humans than to gorillas. However, the divergence times estimated later (using much more sophisticated methods in molecular genetics) do not substantially differ from the very first estimate in 1967.

Divergence times and ancestral effective population size



The sequences of the DNA segments diverge earlier than the species. A large effective population size in the ancestral population (left) preserves different variants of the DNA segments (=alleles) for a longer period of time. Therefore, on average, the gene divergence times (t_A for DNA segment A; t_B for DNA segment B) will deviate more from the time the species diverge (t_S) compared to a small ancestral effective population size (right).

Current methods to determine divergence times use DNA sequence alignments and molecular clocks. Usually the molecular clock is calibrated assuming that the orangutan split from the African apes (including humans) 12-16 MYA. Some studies also include some old world monkeys and set the divergence time of them from hominoids to 25-30 MYA. Both calibration points are based on very little fossil data and have been criticized. If these dates are revised, the divergence times estimated from molecular data will change as well. However, the relative divergence times are unlikely to change. Even if we can't tell absolute divergence times exactly, we can be pretty sure that the divergence time between chimpanzees and humans is about sixfold shorter than between chimpanzees (or humans) and monkeys.

One study (Takahata *et al.*, 1995) used 15 DNA sequence from different regions of the genome from human and chimpanzee and 7 DNA sequences from human, chimpanzee and gorilla. They determined that chimpanzees are more closely related to humans than gorillas. Using various statistical methods, they estimated the divergence time human-chimp to be 4.7 MYA and the divergence time between gorillas and humans (and chimps) to be 7.2 MYA. Additionally they estimated the effective population size of the

common ancestor of humans and chimpanzees to be ~100,000. This was somewhat surprising since the present day effective population size of humans is estimate to be only ~10,000. If true that means that the human lineage would have experienced an immense decrease of its effective population size (and thus genetic diversity) in its evolution.



A and B are two different loci. In the upper figure they fit to the species tree. The DNA that is present in today's gorillas diverged earlier from the DNA that is present in today's humans and chimps. Thus both loci should be more similar between human and chimp than between gorilla and chimp or gorilla and human. In the lower graph, locus A has a more recent common ancestor in human and gorilla compared to the chimp sequence. Whereas chimp and gorilla have a more recent common ancestor for locus B. Here the gene trees are incongruent to the species tree.

Another study (Chen & Li, 2001) sequenced 53 non-repetitive, intergenic DNA segments from a human, a chimpanzee, a gorilla, and orangutan. When the DNA sequences were concatenated to a single long sequence, the generated neighbor-joining tree supported the *Homo-Pan* clade with 100% bootstrap (that is that humans and chimpanzees are the closest related species of the four). When three species are fairly closely related to each

other (like human, chimpanzee and gorilla), the trees obtained from DNA sequence data may not be congruent with the tree that represents the speciation (species tree). The shorter internodal time span (T_{IN}) the more common are incongruent gene trees. The effective population size (N_e) of the internodal population determines how long genetic lineages are preserved in the population. A higher effective population size causes more incongruent gene trees. Therefore, if the internodal time span is known, the ancestral effective population size of the common ancestor of humans and chimpanzees can be calculated.

When each segment was analyzed individually, 31 supported the *Homo*-*Pan* clade, 10 supported the *Homo*-*Gorilla* clade, and 12 supported the *Pan*-*Gorilla* clade. Using the molecular clock the authors estimated that gorillas split up first 6.2-8.4 MYA and chimpanzees and humans split up 1.6-2.2 million years later (internodal time span) 4.6-6.2 MYA. The internodal time span is useful to estimate the ancestral effective population size of the common ancestor of humans and chimpanzees.

A parsimonious analysis revealed that 24 loci supported the *Homo*-*Pan* clade, 7 supported the *Homo*-*Gorilla* clade, 2 supported the *Pan*-*Gorilla* clade and 20 gave no resolution. Additionally they took 35 protein coding loci from databases. Of these 12 supported the *Homo*-*Pan* clade, 3 the *Homo*-*Gorilla* clade, 4 the *Pan*-*Gorilla* clade and 16 gave no resolution. Therefore only ~70% of the 52 loci that gave a resolution (33 intergenic, 19 protein coding) support the 'correct' species tree. From the fraction of loci which did not support the species tree and the internodal time span they estimated previously, the effective population of the common ancestor of humans and chimpanzees was estimated to be ~52 000 to 96 000. This value is not as high as that from the first study (Takahata), but still much higher than present day effective population size of humans.

A third study (Yang, 2002) used the same dataset that Chen and Li used but estimated the ancestral effective population of 'only' ~12,000 to 21,000, using a different statistical method.

Genetic differences between humans and other great apes

The alignable sequences within genomes of humans and chimpanzees differ by about 35 million single nucleotide substitutions. Additionally about 3% of the complete genomes differ by deletions, insertions and duplications.

Since mutation rate is relatively constant, roughly one half of these changes occurred in the human lineage. Only a very tiny fraction of those fixed differences gave rise to the different phenotypes of humans and chimpanzees and finding those is a great challenge. The vast majority of the differences are neutral and do not affect the phenotype.

Molecular evolution may act in different ways, through protein evolution, gene loss, differential gene regulation and RNA evolution. All are thought to have played some part in human evolution.

Gene loss

Many different mutations can inactivate a gene, but few will change its function in a specific way. Inactivation mutations will therefore be readily available for selection to act on. Gene loss could thus be a common mechanism of evolutionary adaptation (the "less-is-more" hypothesis).

80 genes were lost in the human lineage after separation from the last common ancestor with the chimpanzee. 36 of those were for olfactory receptors. Genes involved in chemoreception and immune response are overrepresented. Another study estimated that 86 genes had been lost.

Hair keratin gene KRTHAP1

A gene for type I hair keratin was lost in the human lineage. Keratins are a major component of hairs. Humans still have nine functional type I hair keratin genes but the loss of that particular gene may have caused the thinning of human body hair. The gene loss occurred relatively recently in human evolution—less than 240,000 years ago.

Myosin gene MYH16

Stedman *et al.* (2004) stated that the loss of the sarcomeric myosin gene MYH16 in the human lineage led to smaller masticatory muscles. They estimated that the mutation that led to the inactivation (a two base pair deletion) occurred 2.4 million years ago, predating the appearance of *Homo ergaster/erectus* in Africa. The period that followed was marked by a strong increase in cranial capacity, promoting speculation that the loss of the gene may have removed an evolutionary constraint on brain size in the genus *Homo*.

Another estimate for the loss of the MYH16 gene is 5.3 million years ago, long before *Homo* appeared.

Other

- CASPASE12, a cysteinyl aspartate proteinase

Gene addition

Segmental duplications (SDs or LCRs) have had roles in creating new primate genes and shaping human genetic variation.

Selection pressures

Human accelerated regions are areas of the genome that differ between humans and chimpanzees to a greater extent than can be explained by genetic drift over the time since the two species shared a common ancestor. These regions show signs of being subject to natural selection, leading to the evolution of distinctly human traits. Two examples are

HAR1F, which is believed to be related to brain development and HAR2 (a.k.a HACNS1) that may have played a role in the development of the opposable thumb.

Genetic differences between humans and Neanderthals

An international group of scientists completed a draft sequence of the Neanderthal genome in May 2010. The results indicate some breeding between humans and Neanderthals as the genomes of non-African humans have 1-4% more in common with Neanderthals than do the genomes of subsaharan Africans. Neanderthals and most humans share a lactose-intolerant variant of the lactase gene that encodes an enzyme that is unable to break down lactose in milk after weaning. Humans and Neanderthals also share the FOXP2 gene variant associated with brain development and with speech in humans, indicating that Neanderthals may have been able to speak. Chimps have two amino acid differences in FOXP2 compared with human and Neanderthal FOXP2.

Sequence divergence between humans and apes

The draft sequence of the common chimpanzee genome published in the summer 2005 showed the regions that are similar enough to be aligned with one another account for 2400 million of the human genome's 3164.7 million bases – that is, 75.8% of the genome. This 75.8% of the human genome is 1.23% different from the chimpanzee genome in single nucleotide polymorphisms (changes of single DNA "letters" in the genome). Another type of difference, called indels (insertions/deletions) account for another ~3 % difference between the alignable sequences. In addition, variation in copy number of large segments (> 20 kb) of similar DNA sequence provides a further 2.7% difference between the two species. Hence the total similarity of the genomes could be as low as about 70%.

The figures above do not take into account differences in the organization of the alignable sequences within the genomes of humans and chimps. Short stretches of alignable sequence may be in very different orders and locations within the two genomes. At present we cannot fully assess the difference in structure of the two genomes, because the human genome was used as a scaffold when the chimpanzee draft genome was assembled. When genomes are sequenced, relatively short sequences of DNA are produced, and these sequences have to be fitted together like a jigsaw puzzle. This requires multiple overlapping reads to accurately assemble the overall sequence. The human genome sequence is relatively accurate, with 8 to 9-fold coverage, but the chimpanzee draft genome only has 3.6-fold coverage. The human genome was sequenced using a hierarchical shotgun method which can deal with duplications and difficult-to-assemble sequences better than the whole genome shotgun method that was used for the chimpanzee draft genome. The human genome was used as a template for the assembly of the draft chimpanzee genome, on the assumption that the two genomes would be similar.

Almost half of that 1.23% SNP change belongs to the human at 0.53%, whose genetic variance is lower than a chimp, and just over half to the chimp at 0.7%. If we also take

into account that random "genetic drift" takes up the bulk of the 0.54% difference, then that percentage difference where SNPs have a potential positive impact on human abilities, is between 0.01% and 0.02%. The bonobo is a sibling species of common chimpanzee and is genetically about as different from humans as are common chimps.

Percentage sequence divergence between humans and other hominids

Locus	Human-Chimp	Human-Gorilla	Human-Orangutan
Alu elements	2	-	-
Non-coding (Chr. Y)	1.68 ± 0.19	2.33 ± 0.2	5.63 ± 0.35
Pseudogenes (autosomal)	1.64 ± 0.10	1.87 ± 0.11	-
Pseudogenes (Chr. X)	1.47 ± 0.17	-	-
Noncoding (autosomal)	1.24 ± 0.07	1.62 ± 0.08	3.08 ± 0.11
Genes (K_s)	1.11	1.48	2.98
Introns	0.93 ± 0.08	1.23 ± 0.09	-
Xq13.3	0.92 ± 0.10	1.42 ± 0.12	3.00 ± 0.18
Subtotal for X chromosome	1.16 ± 0.07	1.47 ± 0.08	-
Genes (K_a)	0.8	0.93	1.96

The sequence divergence has generally the following pattern: Human-Chimp < Human-Gorilla << Human-Orangutan, highlighting the close kinship between humans and the African apes. Alu elements diverge quickly due to their high frequency of CpG dinucleotides which mutate roughly 10 times more often than the average nucleotide in the genome. The mutation rate is higher in the male germ line, therefore the divergence in the Y chromosome—which is inherited solely from the father—is higher than in autosomes. The X chromosome is inherited twice as often through the female germ line as through the male germ line and therefore shows slightly lower sequence divergence. The sequence divergence of the Xq13.3 region is surprisingly low between humans and chimpanzees.

Mutations altering the amino acid sequence of proteins (K_a) are the least common. In fact ~29% of all orthologous proteins are identical between human and chimpanzee. The typical protein differs by only two amino acids.

The measures of sequence divergence shown in the table only take the substitutional differences, for example from an A (adenine) to a G (guanine), into account. DNA sequences may however also differ by insertions and deletions (indels) of bases. These are usually stripped from the alignments before the calculation of sequence divergence is performed. The overall sequence divergence between humans and chimpanzees for example is close to 5% if indels would be included.

Modern humans



Map of the migration of modern humans out of Africa, based on mitochondrial DNA. Coloured rings indicate years before present, in thousands.

Molecular biologists starting with Wesley Brown on mtDNA and Allan Wilson on mtDNA have produced observations relevant to human evolution.

Age of the common ancestor

By estimating the rate at which mutations occur in mtDNA, the age of the common ancestral mtDNA type can be estimated: "the common ancestral mtDNA (type a) links mtDNA types that have diverged by an average of nearly 0.57%. Assuming a rate of 2%-4% per million years, this implies that the common ancestor of all surviving mtDNA types existed 140,000-290,000 years ago." This observation is robust, and this common direct female line ancestor (or mitochondrial most recent common ancestor (mtMRCA)) of all extant humans has become known as Mitochondrial Eve. The observation that the mtMRCA is the direct matrilineal ancestor of all living humans does not mean either that she was the first anatomically modern human, nor that no other female humans lived concurrently with her. Other women would have lived at the same time and passed nuclear genes down to living humans, but their mitochondrial lineages were lost over time. This could be due to random events such as producing only male children.

African origin for modern humans

There is evidence that modern human mtDNA has an African origin: "We infer from the tree of minimum length... that Africa is a likely source of the human mitochondrial gene pool. This inference comes from the observation that one of the two primary branches leads exclusively to African mtDNAs... while the second primary branch also leads to African mtDNAs... By postulating that the common ancestral mtDNA... was African, we minimize the number of intercontinental migrations needed to account for the geographic distribution of mtDNA types."

The broad study of African genetic diversity headed by Sarah Tishkoff found the San people to express the greatest genetic diversity among the 113 distinct populations sampled, making them one of 14 "ancestral population clusters". The research also located the origin of modern human migration in south-western Africa, near the coastal border of Namibia and Angola.

Y chromosome findings

The Y chromosome is much larger than mtDNA, and is relatively homogeneous; therefore it has taken much longer to find distinct lineages and to analyse them. Conversely, because the Y chromosome is so large by comparison, it holds more genetic information. Y chromosome studies show similar findings to those made with mtDNA. The estimate for the age of the ancestral Y chromosome for all extant Y chromosomes is given at about 70,000 years ago and is also placed in Africa; the individual who contributed this Y chromosomal heritage is sometimes referred to as Y chromosome Adam. The difference in dates between Y chromosome Adam and mitochondrial Eve is usually attributed to a higher extinction rate for Y chromosomes due to greater differential reproductive success between individual men, which means that a small number of very successful men may produce many children, while a larger number of less successful men will produce far fewer children.

Chapter- 4

Human Mitochondrial Genetics

Human mitochondrial genetics is the study of the genetics of the DNA contained in human mitochondria. Mitochondria are small structures in cells that generate energy for the cell to use, and are hence referred to as the "powerhouses" of the cell.

Mitochondrial DNA (mtDNA) is not transmitted through nuclear DNA (nDNA). In humans, as in most multicellular organisms, mitochondrial DNA is inherited only from the mother's ovum.

Mitochondrial inheritance is therefore non-Mendelian, as Mendelian inheritance presumes that half the genetic material of a fertilized egg (zygote) derives from each parent.

Eighty percent of mitochondrial DNA codes for functional mitochondrial proteins, and therefore most mitochondrial DNA mutations lead to functional problems, which may be manifested as muscle disorders (myopathies).

Understanding the genetic mutations that affect mitochondria can help us to understand the inner workings of cells and organisms, as well as helping to suggest methods for successful therapeutic tissue and organ cloning, and to treatments or possibly cures for many devastating muscular disorders.

Mitochondrial function and genome

Because they provide 36 molecules of ATP per glucose molecule in contrast to the 2 ATP molecules produced by glycolysis, mitochondria are essential to all higher organisms for sustaining life. The mitochondrial diseases are genetic disorders carried specifically in mitochondrial DNA; slight problems with any one of the numerous enzymes used by the mitochondria can be devastating to the cell, and in turn, to the organism.

Membrane complexes

The processes carried out by the electron transport chain are mediated by protein complexes (named Complexes I-V, DHO-QO, ETF-QO, and ANT). Complex I, or NADH : coenzyme Q oxidoreductase, uses the energy in NADH to pump protons into the intermembrane space of the mitochondrion, pumping 2 protons per electron and passing 2 electrons via coenzyme Q to complex III or coenzyme Q : cytochrome c oxidoreductase. Complex II or succinate : coenzyme Q oxidoreductase accepts energy from succinate produced in the citric acid cycle and passes it via coenzyme Q to complex III. Complex III pumps 1 protons per electron and passes 1 electron via cytochrome c to complex IV or Cytochrome C : O_2 Oxidoreductase. Complex IV pumps 1 protons into the space between the mitochondrion's two membranes before passing the electron to O_2 which reacts to form water. Complex V (ATP synthase) is a rotary complex which allows approximately (determining the actual number is very difficult) 10 protons to enter the mitochondrial matrix along their concentration gradients. It uses the energy from the gradient to form the bond between ADP and the phosphate group to create ATP. The electron transfer flavoprotein : coenzyme Q oxidoreductase is also an electron-transporting molecule and is involved in the breakdown of fatty acids and amino acids. ANT (adenine nucleotide translocator) is also involved in oxidative phosphorylation as an energy carrying molecule. Each of these eight complexes plays a vital role in the health of the cell and any slight mutation in any one of the proteins that make up these complexes can lead to cell death or stress, which can both in turn lead to a number of diseases.

Genome

Mitochondrial DNA (mtDNA) is present in mitochondria as a circular molecule and in most species codes for 13 or 14 proteins involved in the electron transfer chain, 2 rRNA subunits and 22 tRNA molecules (all necessary for protein synthesis). The number of proteins involved in the electron transfer chain is much larger than 13 or 14, but the others are coded by the nuclear DNA.

In total, the mitochondrion hosts about 3000 proteins, but only about 13 of them are coded on the mitochondrial DNA. Most of the 3000 proteins are involved in a variety of processes other than ATP production, such as porphyrin synthesis. Only about 3% of them code for ATP production proteins. This means most of the genetic information coding for the protein makeup of mitochondria is in chromosomal DNA and is involved in processes other than ATP synthesis. This increases the chances that a mutation that will affect a mitochondrion will occur in chromosomal DNA, which is inherited in a Mendelian pattern. Another result is that a chromosomal mutation will affect a specific tissue due to its specific needs, whether those may be high energy requirements or a need for the catabolism or anabolism of a specific neurotransmitter or nucleic acid. Because several copies of the mitochondrial genome are carried by each mitochondrion (2-10 in humans), mitochondrial mutations can be inherited maternally by mtDNA mutations which are present in mitochondria inside the oocyte before fertilization, or (as stated above) through mutations in the chromosomes.

In humans, the heavy strand of mtDNA carries 28 genes and the light strand of mtDNA carries only 9 genes. Eight of the 9 genes on the light strand code for mitochondrial tRNA molecules. Human mtDNA consists of 16,569 nucleotide pairs. The entire molecule is regulated by only one regulatory region which contains the origins of replication of both heavy and light strands. The entire human mitochondrial DNA molecule has been mapped. The rate of mutation in mtDNA is calculated to be about ten times greater than that of nuclear DNA, possibly due to a paucity of DNA repair mechanisms. This high mutation rate leads to a high variation between mitochondria, not only among different species but even within the same species. It is calculated that if two humans are chosen randomly and their mtDNA is tested, they will have an average of between fifty and seventy different nucleotides. This may not seem like much, but when compared to the total number of nucleotides of a human mitochondrial DNA molecule (16,569), as much as 0.42% of the mtDNA varies between two people.

Genetic code variants

The genetic code is, for the most part, universal, with few exceptions: mitochondrial genetics includes some of these. For most organisms the "stop codons" are “UAA”, “UAG”, and “UGA”. In vertebrate mitochondria “AGA” and “AGG” are also stop codons, but not “UGA”, which codes for tryptophan instead. “AUA” codes for isoleucine in most organisms but for methionine in vertebrate mitochondrial mRNA.

There are many other variations among the codes used by other mitochondrial m/tRNA, which happened not to be harmful to their organisms, and which can be used as a tool (along with other mutations among the mtDNA/RNA of different species) to determine relative proximity of common ancestry of related species. (The more related two species are, the more mtDNA/RNA mutations will be the same in their mitochondrial genome).

Using these techniques, it is estimated that the first mitochondria arose around 1.5 billion years ago. A generally accepted hypothesis is that mitochondria originated as an aerobic prokaryote in a symbiotic relationship within an anaerobic eukaryote.

Inheritance patterns



Mitochondrial Inheritance Patterns

Because mitochondrial diseases (diseases due to malfunction of mitochondria) can be inherited both maternally and through chromosomal inheritance, the way in which they are passed on from generation to generation can vary greatly depending on the disease. Mitochondrial genetic mutations that occur in the nuclear DNA can occur in any of the chromosomes (depending on the species). Mutations inherited through the chromosomes can be autosomal dominant or recessive and can also be sex-linked dominant or recessive. Chromosomal inheritance follows normal Mendelian laws, despite the fact that the phenotype of the disease may be masked.

Because of the complex ways in which mitochondrial and nuclear DNA "communicate" and interact, even seemingly simple inheritance is hard to diagnose. A mutation in chromosomal DNA may change a protein that regulates (increases or decreases) the production of another certain protein in the mitochondria or the cytoplasm; this may lead to slight, if any, noticeable symptoms. On the other hand, some devastating mtDNA mutations are easy to diagnose because of their widespread damage to muscular, neural, and/or hepatic tissues (among other high-energy and metabolism-dependent tissues) and because they are present in the mother and all the offspring.

Mitochondrial genome mutations are passed on 100% of the time from mother to all her offspring. The number of affected mtDNA molecules inherited by a specific offspring can vary greatly because

- the mitochondria within the fertilized oocyte is what the new life will have to begin with (in terms of mtDNA),
- the number of affected mitochondria varies from cell (in this case, the fertilized oocyte) to cell depending both on the number it inherited from its mother cell and environmental factors which may favor mutant or wildtype mitochondrial DNA,
- the number of mtDNA molecules in the mitochondria varies from around two to ten.

It is possible, even in twin births, for one baby to receive more than half mutant mtDNA molecules while the other twin may receive only a tiny fraction of mutant mtDNA molecules with respect to wildtype (depending on how the twins divide from each other and how many mutant mitochondria happen to be on each side of the division). In a few cases, some mitochondria or a mitochondrion from the sperm cell enters the oocyte but paternal mitochondria are actively decomposed.

Replication, repair, transcription, and translation

Mitochondrial replication is controlled by nuclear genes and is specifically suited to make as many mitochondria as that particular cell needs at the time. Human mitochondrial DNA (mtDNA) has three promoters, H1, H2, and L (heavy strand 1, heavy strand 2, and light strand promoters). The H2 promoter transcribes almost the entire heavy strand and the L promoter transcribes the entire light strand. The H1 promoter causes the transcription of the two mitochondrial rRNA molecules. When transcription takes place on the heavy strand a polycistronic transcript is created. The light strand produces either small transcripts, which can be used as primers, or one long transcript. The production of primers occurs by processing of light strand transcripts with the Mitochondrial RNase MRP (Mitochondrial RNA Processing). The requirement of transcription to produce primers links the process of transcription to mtDNA replication. Full length transcripts are cut into functional tRNA, rRNA, and mRNA molecules. The process of transcription initiation in mitochondria involves three types of proteins: the mitochondrial RNA polymerase (POLRMT), mitochondrial transcription factor A (TFAM), and mitochondrial transcription factors B1 and B2 (TFB1M, TFB2M). POLRMT, TFAM, and TFB1M or TFB2M assemble at the mitochondrial promoters and begin transcription. The actual molecular events that are involved in initiation are unknown, but these factors make up the basal transcription machinery and have been shown to function in vitro. Mitochondrial translation is still not very well understood. In vitro translations have still not been successful, probably due to the difficulty of isolating sufficient mt mRNA, functional mt rRNA, and possibly because of the complicated changes that the mRNA undergoes before it is translated.

Mitochondrial DNA polymerase

The Mitochondrial DNA Polymerase (Pol gamma, encoded by the POLG gene) is used in the copying of mtDNA during replication. Because the two (heavy and light) strands on the circular mtDNA molecule have different origins of replication, it replicates in a D-loop mode. One strand begins to replicate first, displacing the other strand. This continues

until replication reaches the origin of replication on the other strand, at which point the other strand begins replicating in the opposite direction. This results in two new mtDNA molecules. Each mitochondrion has several copies of the mtDNA molecule and the number of mtDNA molecules is a limiting factor in mitochondrial fission. After the mitochondrion has enough mtDNA, membrane area, and membrane proteins, it can undergo fission (very similar to that which bacteria use) to become two mitochondria. Evidence suggests that mitochondria can also undergo fusion and exchange (in a form of crossover) genetic material among each other. Mitochondria sometimes form large matrices in which fusion, fission, and protein exchanges are constantly occurring. mtDNA shared among mitochondria (despite the fact that they can undergo fusion).

Damage and transcription error

Mitochondrial DNA is susceptible to damage from free oxygen radicals from mistakes that occur during the production of ATP through the electron transport chain. These mistakes can be caused by genetic disorders, cancer, and temperature variations. These radicals can damage mtDNA molecules or change them, making it hard for mitochondrial polymerase to replicate them. Both cases can lead to deletions, rearrangements, and other mutations. Recent evidence has suggested that mitochondria have enzymes that proofread mtDNA and fix mutations that may occur due to free radicals. It is believed that a DNA recombinase found in mammalian cells is also involved in a repairing recombination process. Deletions and mutations due to free radicals have been associated with the aging process. It is believed that radicals cause mutations which lead to mutant proteins, which in turn lead to more radicals. This process takes many years and is associated with some aging processes involved in oxygen-dependent tissues such as brain, heart, muscle, and kidney. Auto-enhancing processes such as these are possible causes of degenerative diseases including Parkinson’s, Alzheimer’s, and coronary artery disease.

Chromosomally mediated mtDNA replication errors

Because mitochondrial growth and fission are mediated by the nuclear DNA, mutations in nuclear DNA can have a wide array of effects on mtDNA replication. Despite the fact that the loci for some of these mutations have been found on human chromosomes, specific genes and proteins involved have not yet been isolated. Mitochondria need a certain protein to undergo fission. If this protein (made by the nucleus) is not present, the mitochondria grow but they do not divide. This leads to giant, inefficient mitochondria. Mistakes in chromosomal genes or their products can also affect mitochondrial replication more directly by inhibiting mitochondrial polymerase and can even cause mutations in the mtDNA directly and indirectly. Indirect mutations are most often caused by radicals created by defective proteins made from nuclear DNA.

Mitochondrial diseases

Mitochondrial diseases range in severity from asymptomatic to fatal, and are most commonly due to inherited rather than acquired mutations of mitochondrial DNA. A given mitochondrial mutation can cause various diseases depending on the severity of the

problem in the mitochondria and the tissue the affected mitochondria are in. Conversely, several different mutations may present themselves as the same disease. This almost patient-specific characterization of mitochondrial diseases makes them very hard to accurately recognize, diagnose and trace. Some diseases are observable at or even before birth (many causing death) while others do not show themselves until late adulthood (late-onset disorders). This is because the number of mutant versus wildtype mitochondria varies between cells and tissues, and is continuously changing. Because cells have multiple mitochondria, different mitochondria in the same cell can have different variations of the mtDNA. This condition is referred to as heteroplasmy. When a certain tissue reaches a certain ratio of mutant versus wildtype mitochondria, a disease will present itself. The ratio varies from person to person and tissue to tissue (depending on its specific energy, oxygen, and metabolism requirements, and the effects of the specific mutation). Mitochondrial diseases are very numerous and different. Apart from diseases caused by abnormalities in mitochondrial DNA, many diseases are suspected to be associated in part by mitochondrial dysfunctions, such as diabetes mellitus, forms of cancer and cardiovascular disease, lactic acidosis, specific forms of myopathy, osteoporosis, Alzheimer's disease, Parkinsons's disease, stroke, Male infertility and which are also believed to play a role in the aging process.

Chapter- 5

XY Sex-Determination System



Drosophila sex-chromosomes

The **XY sex-determination system** is the sex-determination system found in humans, most other mammals, some insects (*Drosophila*) and some plants (*Ginkgo*). In this system, females have two of the same kind of sex chromosome (XX), and are called the homogametic sex. Males have two distinct sex chromosomes (XY), and are called the heterogametic sex. However, an opposite scheme is found in birds.

The XY sex determination system was first described independently by Nettie Stevens and Edmund Beecher Wilson in 1905.

History

Ancient ideas on gender determination

Since ancient times, people believed that the gender of an infant is determined by how much heat a man's sperm had during insemination. Aristotle wrote that:

> “ ...the semen of the male differs from the corresponding secretion of the female in that it contains a principle within itself of such a kind as to set up movements also in the embryo and to concoct thoroughly the ultimate nourishment, whereas the secretion of the female contains material alone. If, then, the male element prevails it draws the female element into itself, but if it is prevailed over it changes into the opposite or is destroyed. ”

Aristotle claimed that the male principle was the driver behind gender determination, such that if the male principle was insufficiently expressed during reproduction, the fetus would develop as a female. In contrast, modern genetics has developed a view on sex determination in which no one single factor is responsible with determining gender, a number of pro-male, anti-male and pro-female genes being responsible.

Beginnings of genetics of sex

Edmund Beecher Wilson and Nettie Stevens are credited with discovering in 1905 the chromosomal XY sex-determination system, the idea that males have XY sex chromosomes and females have XX sex chromosomes.

The first clues to the existence of a factor which determines the development of testis in mammalians came from experiments carried out by Alfred Jost, who castrated embryonic rabbits in utero and noticed that they all developed as female. In the wake of Jost's experiments, C. E. Ford and his team discovered that the Y gene was needed for a foetus to develop as male when they examined patients with Turner's syndrome, who grew up as phenotypic females, and found them to be X0 (hemizygous for X and no Y). All these observations lead to a consensus that a dominant gene which determines testis development (TDF) must exist on the mammalian chromosome Y.

The search for a testis-determining factor (TDF) lead a team of scientistsin 1990 to discover a region of the Y chromosome which is necessary for the male sex determination and which was named SRY (**S**ex-determining **R**egion of the **Y** chromosome).

Mechanisms

Some species (including most mammals) have a gene or genes on the Y chromosome that determine maleness. In the case of humans, a single gene (*SRY*) on the Y chromosome acts as a signal to set the developmental pathway towards maleness. Other mammals use several genes on the Y chromosome for that same purpose. Not all male-specific genes are located on the Y chromosome.

Other species (including most *Drosophila* species) use the presence of two X chromosomes to determine femaleness. One X chromosome gives putative maleness. The presence of Y chromosome genes is required for normal male development.

Humans, as well as some other organisms, can have a chromosomal arrangement that is contrary to their phenotypic sex, that is, XX males or XY females. See, for example, XX male syndrome and Androgen insensitivity syndrome.

Do note that birds have a similar (but reversed) system of sex determination (ZW sex-determination system). Here, it is the females which are heterogametic (ZW), while males are homogametic (ZZ).

Recent studies on the genetic factors which influence gender traits

For a long time, biologists had believed that the female form was the default template for the mammalian foetuses of both sexes. After the discovery of the testis-determining gene SRY, many scientists still believed that the genetic mechanism which determines a foetus to develop into a male form was initiated by the SRY gene, which was thought to be responsible for the production of testosterone and its overall effects on body and brain development. This perspective still shared the classical way of thinking, that in order to produce two sexes, nature has developed a default, female pathway, and an active pathway, by which male genes would initiate the process of determining a male sex, as something which is developed in addition to and based on the default female form. This view is no longer considered accurate by most scientists which study the genetics of sex. In an interview for the *Rediscovering Biology* website, researcher Eric Vilain described how the paradigm changed since the discovery of the SRY gene:

> “For a long time we thought that SRY would activate a cascade of male genes. It turns out that the sex determination pathway is probably more complicated and SRY may in fact inhibit some anti-male genes.
>
> The idea is instead of having a simplistic mechanism by which you have pro-male genes going all the way to make a male, in fact there is a solid balance between pro-male genes and anti-male genes and if there is a little too much of anti-male genes, there may be a female born and if there is a little too much of”

pro-male genes then there will be a male born.

> We [are] entering this new era in molecular biology of sex determination where it's a more subtle dosage of genes, some pro-males, some pro-females, some anti-males, some anti-females that all interplay with each other rather than a simple linear pathway of genes going one after the other which makes it very fascinating but very complicated to study.

In mammals, including humans, the SRY gene is responsible with triggering the development of non-differentiated gonads into testes, rather than ovaries. However, there are cases in which testes can develop in the absence of an SRY gene. In these cases, the SOX9 gene, involved in the development of testes, can induce their development without the aid of SRY. In the absence of SRY and SOX9, no testes can develop and the path is clear for the development of ovaries. Even so, the absence of the SRY gene or the silencing of the SOX9 gene are not enough to trigger sexual differentiation of a foetus in the female direction. A recent finding indicates that ovary development and maintenance is an active process, regulated by the expression of a "pro-female" gene, FOXL2. In an interview for the *TimesOnline* edition, study co-author Robin Lovell-Badge explained the significance of the discovery:

> “ We take it for granted that we maintain the sex we are born with, including whether we have testes or ovaries. But this work shows that the activity of a single gene, FOXL2, is all that prevents adult ovary cells turning into cells found in testes. ”

Implications for human health and social policy

Looking into the genetic determinants of human sex can have wide-ranging consequences. Scientists have been studying different sex determination systems in fruit flies and animal models to be able to understand how the genetics of sexual differentiation can influence biological processes like reproduction, ageing and disease. Since many genetic mechanisms involved in determining sexually dimorphic traits have been preserved from the fruitflies to mice and humans, understanding how these genetic mechanisms work can lead to improved health care which takes into account sex differences and also to changes in how people understand and perceive sex differences, which can influence how they treat each other in social settings.

Chapter- 6

X Chromosome



Scheme of the X chromatid



Nucleus of a female amniotic fluid cell. Top: Both X-chromosome territories are detected by FISH. Shown is a single optical section made with a confocal microscope. Bottom: Same nucleus stained with DAPI and recorded with a CCD camera. The Barr body is indicated by the arrow, it identifies the inactive X (Xi).

The **X chromosome** is one of the two sex-determining chromosomes in many animal species, including mammals (the other is the Y chromosome). It is a part of the XY sex-determination system and X0 sex-determination system. The **X** chromosome was named for its unique properties by early researchers, which resulted in the naming of its counterpart **Y** chromosome, for the next letter in the alphabet, after it was discovered later.

In humans

Function

The sex chromosomes X X are one of the 23 homologous pairs of chromosomes in a female. The X chromosome spans more than 153 million base pairs (the building material of DNA) and represents about 5% of the total DNA in women's cells, 2.5% in men's.

Each person normally has one pair of sex chromosomes in each cell. Females have two X chromosomes, whereas males have one X and one Y chromosome. Both males and females retain one of their mother's X chromosomes, and females retain their second X chromosome from their father. Since the father retains his X chromosome from his mother, a human female has one X chromosome from her paternal grandmother (father's side), and one X chromosome from her mother.

Identifying genes on each chromosome is an active area of genetic research. Because researchers use different approaches to predict the number of genes on each chromosome, the estimated number of genes varies. The X chromosome contains about 2000 genes compared to the Y chromosome containing 78 genes, out of the estimated 20,000 to 25,000 total genes in the human genome. Genetic disorders that are due to mutations in genes on the X chromosome are described as **X linked**.

The X chromosome carries a couple of thousand genes but few, if any, of these have anything to do directly with sex determination. Early in embryonic development in females, one of the two X chromosomes is randomly and permanently inactivated in nearly all somatic cells (cells other than egg and sperm cells). This phenomenon is called X-inactivation or Lyonization, and creates a Barr body. X-inactivation ensures that females, like males, have one functional copy of the X chromosome in each body cell. It was previously assumed that only one copy is actively used. However, recent research suggests that the Barr body may be more biologically active than was previously supposed.

Structure

It is theorized by Ross et al. 2005 and Ohno 1967 that the X-chromosome is at least partially derived from the autosomal (non-sex-related) genome of other mammals evidenced from interspecies genomic sequence alignments.

The X-chromosome is notably larger and has a more active euchromatin region than its Y-chromosome counterpart. Further comparison of the X and Y reveal regions of homology between the two. However, the corresponding region in the Y appears far shorter and lacks regions that are conserved in the X throughout primate species, implying a genetic degeneration for Y in that region. Because males have only one X-chromosome, they are more likely to have an X chromosome-related disease.

It is estimated that about 10% of the genes encoded by the X-chromosome are associated with a family of "CT" genes, so named because they encode for markers found in both tumor cells (in **C**ancer patients) as well as in the human testis (in healthy patients).

Role in diseases



Numerical abnormalities

Klinefelter's syndrome:

- Klinefelter's syndrome is caused by the presence of one or more extra copies of the X chromosome in a male's cells. Extra genetic material from the X chromosome interferes with male sexual development, preventing the testicles from functioning normally and reducing the levels of testosterone.
- Males with Klinefelter's syndrome typically have one extra copy of the X chromosome in each cell, for a total of two X chromosomes and one Y chromosome (47,XXY). It is less common for affected males to have two or three extra X chromosomes (48,XXXY or 49,XXXXY) or extra copies of both the X and Y chromosomes (48,XXYY) in each cell. The extra genetic material may lead

to tall stature, learning and reading disabilities, and other medical problems. The average IQ in Klinefelter syndrome is in the normal range. When additional X and/or Y chromosomes are present in 48,XXXY, 48,XXYY, or 49,XXXXY, developmental delays and cognitive difficulties can be more severe and mild intellectual disability may be present.
- Klinefelter's syndrome can also result from an extra X chromosome in only some of the body's cells. These cases are called mosaic 46,XY/47,XXY.

Triple X syndrome (also called 47,XXX or trisomy X):

- This syndrome results from an extra copy of the X chromosome in each of a female's cells. Females with trisomy X have three X chromosomes, for a total of 47 chromosomes per cell. The average IQ of females with this syndrome is 90, while the average IQ of their normal siblings is 100. Their stature on average is taller than normal females. They are fertile and their children do not inherit the condition.

- Females with more than one extra copy of the X chromosome (48, XXXX syndrome or 49, XXXXX syndrome) have been identified, but these conditions are rare.

Turner syndrome:

- This results when each of a female's cells has one normal X chromosome and the other sex chromosome is missing or altered. The missing genetic material affects development and causes the features of the condition, including short stature and infertility.
- About half of individuals with Turner syndrome have monosomy X (45,X), which means each cell in a woman's body has only one copy of the X chromosome instead of the usual two copies. Turner syndrome can also occur if one of the sex chromosomes is partially missing or rearranged rather than completely missing. Some women with Turner syndrome have a chromosomal change in only some of their cells. These cases are called Turner syndrome mosaics (45,X/46,XX).

Other disorders

XX male syndrome is a rare disorder, where the SRY region of the Y chromosome has recombined to be located on one of the X chromosomes. As a result, the XX combination after fertilization has the same effect as a XY combination, resulting in a male. However, the other genes of the X chromosome cause feminization as well.

X-linked endothelial corneal dystrophy is an extremely rare disease of cornea associated with Xq25 region. Lisch epithelial corneal dystrophy is associated with Xp22.3.

Megalocornea 1 is associated with Xq21.3-q22

Chapter- 7

Y Chromosome



Human Y-chromatid

The **Y chromosome** is one of the two sex-determining chromosomes in most mammals, including humans. In mammals, it contains the gene SRY, which triggers testis development if present. The human Y chromosome is composed of about 60 million base pairs. DNA in the Y chromosome is passed from father to son, and Y-DNA analysis may thus be used in genealogy research.

Overview

Most mammals have one pair of sex chromosomes in each cell. Males have one Y chromosome and one X chromosome, while females have two X chromosomes. In mammals, the Y chromosome contains a gene, SRY, which triggers embryonic development as a male. The Y chromosomes of humans and other mammals also contain other genes needed for normal sperm production.

There are exceptions, however. For example, the platypus relies on an XY sex-determination system based on five pairs of chromosomes. Platypus sex chromosomes in fact appear to bear a much stronger homology (similarity) with the avian Z chromosome, and the SRY gene so central to sex-determination in most other mammals is apparently not involved in platypus sex-determination. Among humans, some men have two Xs and

a Y, or one X and two Ys, and some women have three Xs or a single X instead of a double X. There are other exceptions in which SRY is damaged (leading to an XY female), or copied to the X (leading to an XX male).

Origins and evolution

Before Y-chromosome

Many ectothermic vertebrates have no sex chromosomes. If they have different sexes, sex is determined environmentally rather than genetically. For some of them, especially reptiles, sex depends on the incubation temperature; others are hermaphroditic (meaning they contain both male and female gametes in the same individual).

Origin

The X and Y chromosomes are thought to have evolved from a pair of identical chromosomes, termed autosomes, when an ancestral mammal developed an allelic variation, a so-called 'sex locus' - simply possessing this allele caused the organism to be male. The chromosome with this allele became the Y chromosome, while the other member of the pair became the X chromosome. Over time, genes which were beneficial for males and harmful to (or had no effect on) females either developed on the Y chromosome, or were acquired through the process of translocation..

Until recently, the X and Y chromosomes were thought to have diverged around 300 million years ago. However recent research, particularly that stemming from the sequencing of the platypus genome, has suggested that the XY sex-determination system wouldn't have been present more than 166 million years ago, at the split of the monotremes from other mammals. This reestimation of the age of the therian XY system is based on the finding that sequences that are on the X chromosomes of marsupials and eutherian mammals are present on the autosomes of platypus and birds. The older estimate was based on erroneous reports that the platypus X chromosomes contained these sequences.

Recombination inhibition

Recombination between the X and Y chromosomes proved harmful - it resulted in males without necessary genes formerly found on the Y chromosome, and females with unnecessary or even harmful genes previously only found on the Y chromosome. As a result, genes beneficial to males accumulated near the sex-determining genes, and recombination in this region was suppressed in order to preserve this male specific region. Over time, the Y chromosome changed in such a way as to inhibit the areas around the sex determining genes from recombining at all with the X chromosome. As a result of this process 95% of the human Y chromosome is unable to recombine.

Shrinking

The human Y chromosome has lost 1,393 of its 1,438 original genes over the course of its existence. With a rate of genetic loss of 4.6 genes per million years, the Y chromosome may potentially lose complete function within the next 10 million years. Comparative genomic analysis, however, reveals that many mammalian species are experiencing a similar loss of function in their heterozygous sex chromosome. Degeneration may simply be the fate of all nonrecombining sex chromosomes due to three common evolutionary forces: high mutation rate, inefficient selection and genetic drift. On the other hand, recent comparisons of the human and chimpanzee Y chromosomes show that the human Y chromosome has not lost any genes since the divergence of humans and chimpanzees between 6-7 million years ago, providing direct evidence that the linear extrapolation model may be flawed.

High mutation rate

The human Y chromosome is particularly exposed to high mutation rates due to the environment in which it is housed. The Y chromosome is passed exclusively through sperm, which undergo multiple cell divisions during gametogenesis. Each cellular division provides further opportunity to accumulate base pair mutations. Additionally, sperm are stored in the highly oxidative environment of the testis, which encourages further mutation. These two conditions combined put the Y chromosome at a risk of mutation 4.8 times greater than the rest of the genome.

Inefficient selection

Without the ability to recombine during meiosis, the Y chromosome is unable to expose individual alleles to natural selection. Deleterious alleles are allowed to "hitchhike" with beneficial neighbors, thus propagating maladapted alleles in to the next generation. Conversely, advantageous alleles may be selected against if they are surrounded by harmful alleles (background selection). This inability to sort through its gene content, the Y chromosome is particularly prone to the accumulation of "junk" DNA. Massive accumulations of retrotransposable elements are scattered throughout the Y. The random insertion of DNA segments often disrupt encoded gene sequences and render them nonfunctional. However, the Y chromosome has no way of weeding out these "jumping genes". Without the ability to isolate alleles, selection cannot effectively act upon them.

Genetic drift

Even if a well adapted Y chromosome manages to maintain genetic activity by avoiding mutation accumulation, there is no guarantee it will be passed down to the next generation. The population size of the Y chromosome is inherently limited to 1/4 that of autosomes: diploid organisms contain two copies of autosomal chromosomes while only half the population contains 1 Y chromosome. Thus, genetic drift is an exceptionally strong force acting upon the Y chromosome. Through sheer random assortment, an adult male may never pass on his Y chromosome if he only has female offspring. Thus,

although a male may have a well adapted Y chromosome free of excessive mutation, it may never make it in to the next gene pool. The repeat random loss of well-adapted Y chromosomes, coupled with the tendency of the Y chromosome to evolve to have more deleterious mutations rather than less for reasons described above, contributes to the species-wide degeneration of Y chromosomes through Muller's ratchet.

Gene conversion

In 2003, researchers from MIT discovered a process which may slow down the process of degradation. They found that human Y chromosome is able to "recombine" with itself, using palindrome base pair sequences. Such a "recombination" is called gene conversion or *recombinational loss of heterozygosity* (RecLOH).

In the case of the Y chromosomes, the palindromes are not noncoding DNA; these strings of bases contain functioning genes important for male fertility. Most of the sequence pairs are greater than 99.97% identical. The extensive use of gene conversion may play a role in the ability of the Y chromosome to edit out genetic mistakes and maintain the integrity of the relatively few genes it carries. In other words, since the Y chromosome is single, it has duplicates of its genes on itself instead of having a second, homologous, chromosome. When errors occur, it can use other parts of itself as a template to correct them.

Findings were confirmed by comparing similar regions of the Y chromosome in humans to the Y chromosomes of chimpanzees, bonobos and gorillas. The comparison demonstrated that the same phenomenon of gene conversion appeared to be at work more than 5 million years ago, when humans and the non-human primates diverged from each other.

Future evolution

In the terminal stages of the degeneration of the Y chromosome, other chromosomes increasingly take over genes and functions formerly associated with it. Finally, the Y chromosome disappears entirely, and a new sex-determining system arises. Several species of rodent in the sister families Muridae and Cricetidae have reached these stages, in the following ways:

- The Transcaucasian mole vole, *Ellobius lutescens*, the Zaisan mole vole, *Ellobius tancrei*, and the Japanese spinous country rats *Tokudaia osimensis* and *Tokudaia muenninki*, have lost the Y chromosome and SRY entirely. *Tokudaia* spp. have relocated some other genes ancestrally present on the Y chromosome to the X chromosome. Both genders of *Tokudaia* spp. and *Ellobius lutescens* have an XO genotype, whereas all *Ellobius tancrei* possess an XX genotype. The new sex-determining system for these rodents remains unclear.
- The wood lemming *Myopus schisticolor*, the arctic lemming, *Dicrostonyx torquatus*, and multiple species in the grass mouse genus *Akodon* have evolved fertile females who possess the genotype generally coding for males, XY, in

addition to the ancestral XX female, through a variety of modifications to the X and Y chromosomes.
- In the creeping vole, *Microtus oregoni*, the females, with just one X chromosome each, produce X gametes only, and the males, XY, produce Y gametes, or gametes devoid of any sex chromosome, through nondisjunction.

Outside of the rodent family, the black muntjac, *Muntiacus crinifrons*, evolved new X and Y chromosomes through fusions of the ancestral sex chromosomes and autosomes. Primate Y chromosomes, including in humans, have degenerated so much that primates will also evolve new sex determination systems relatively soon, in about 14 million years in humans.

Human Y chromosome

In humans, the Y chromosome spans about 58 million base pairs (the building blocks of DNA) and represents approximately 2% of the total DNA in a male cell. The human Y chromosome contains 86 genes, which code for only 23 distinct proteins. Traits that are inherited via the Y chromosome are called holandric traits.

The human Y chromosome is unable to recombine with the X chromosome, except for small pieces of pseudoautosomal regions at the telomeres (which comprise about 5% of the chromosome's length). These regions are relics of ancient homology between the X and Y chromosomes. The bulk of the Y chromosome which does not recombine is called the "NRY" or non-recombining region of the Y chromosome. It is the SNPs in this region which are used for tracing direct paternal ancestral lines.

Genes

Not including pseudoautosomal genes, genes include:

- NRY, with corresponding gene on X chromosome
  - AMELY/AMELX (amelogenin)
  - RPS4Y1/RPS4Y2/RPS4X (Ribosomal protein S4)

- NRY, other
  - AZF1 (azoospermia factor 1)
  - BPY2 (basic protein on the Y chromosome)
  - DAZ1 (deleted in azoospermia)
  - DAZ2
  - PRKY (protein kinase, Y-linked)
  - RBMY1A1
  - SRY (sex-determining region)
  - TSPY (testis-specific protein)
  - USP9Y
  - UTY (ubiquitously transcribed TPR gene on Y chromosome)
  - ZFY (zinc finger protein)

Y-chromosome-linked diseases

Y-chromosome-linked diseases can be of more common types, or very rare ones. Yet, the rare ones still have importance in understanding the function of the Y-chromosome in the normal case.

More common

No vital genes reside only on the Y chromosome, since roughly half of humans (females) do not have Y chromosomes. The only well-defined human disease linked to a defect on the Y chromosome is defective testicular development (due to deletion or deleterious mutation of *SRY*). However, having two X-chromosomes and one Y-chromosome has similar effects. On the other hand, having Y-chromosome polysomy has other effects than masculinization.

Defective Y-chromosome

This results in the person presenting a female phenotype even though that person possesses an XY karyotype (i.e., is born with female-like genitalia). The lack of the second X results in infertility. In other words, viewed from opposite direction, the person goes through defeminization but fails to complete masculinization.

The cause can be seen as an incomplete Y chromosome: the usual karyotype in these cases is 44X, plus a fragment of Y. This usually results in defective testicular development, such that the infant may or may not have fully formed male genitalia internally or externally. The full range of ambiguity of structure may occur, especially if mosaicism is present. When the Y fragment is minimal and nonfunctional, the child usually is a girl with the features of Turner syndrome or mixed gonadal dysgenesis.

XXY

Klinefelter's syndrome (47, XXY) is not an aneuploidy of the Y chromosome, but a condition of having an extra X chromosome, which usually results in defective postnatal testicular function. The mechanism is not fully understood; the extra X does not seem to be due to direct interference with expression of Y genes.

XYY

47,XYY syndrome is caused by the presence of a single extra copy of the Y chromosome in each of a male's cells. 47, XYY males have one X chromosome and two Y chromosomes, for a total of 47 chromosomes per cell. Researchers have found that an extra copy of the Y chromosome is associated with increased stature and an increased incidence of learning problems in some boys and men, but the effects are variable, often minimal, and the vast majority do not know their karyotype. When chromosome surveys were done in the mid-1960s in British secure hospitals for the developmentally disabled, a higher than expected number of patients were found to have an extra Y chromosome.

The patients were mischaracterized as aggressive and criminal, so that for a while an extra Y chromosome was believed to predispose a boy to antisocial behavior (and was dubbed the "criminal karyotype"). Subsequently, in 1968 in Scotland the only ever comprehensive nationwide chromosome survey of prisons found no overrepresentation of 47,XYY men, and later studies found 47,XYY boys and men had the same rate of criminal convictions as 46,XY boys and men of equal intelligence. Thus, the "criminal karyotype" concept is inaccurate and obsolete.

Rare

The following Y-Chromosome-linked diseases are rare, but notable because of their elucidating of the nature of the Y-chromosome.

More than two Y chromosomes

Greater degrees of Y chromosome polysomy (having more than one extra copy of the Y chromosome in every cell, e.g., XYYYY) are rare. The extra genetic material in these cases can lead to skeletal abnormalities, decreased IQ, and delayed development, but the severity features of these conditions are variable.

XX male syndrome

XX male syndrome occurs when there has been a recombination in the formation of the male gametes, causing the SRY-portion of the Y chromosome to move to the X chromosome. When such an X chromosome contributes to the child, the development will lead to a male, because of the SRY gene.

Genetic genealogy

In human genetic genealogy (the application of genetics to traditional genealogy) use of the information contained in the Y chromosome is of particular interest since, unlike other genes, the Y chromosome is passed exclusively from father to son.

Non-mammal Y-chromosome

Many groups of organisms in addition to mammals have Y chromosomes, but these Y chromosomes do not share common ancestry with mammalian Y chromosomes. Such groups include Drosophila, some other insects, some fish, some reptiles, and some plants. In Drosophila melanogaster, the Y chromosome does not trigger male development. Instead, sex is determined by the number of X chromosomes. The *D. melanogaster* Y chromosome does contain genes necessary for male fertility. So XXY *D. melanogaster* are female, and *D. melanogaster* with a single X (X0), are male but sterile. There are some species of Drosophila in which X0 males are both viable and fertile.

ZW-chromosomes

Other organisms have mirror image sex chromosomes: the female is "XY" and the male is "XX", but by convention biologists call a "female Y" a W chromosome and the other a Z chromosome. For example, female birds, snakes, and butterflies have ZW sex chromosomes, and males have ZZ sex chromosomes.

Chapter- 8

Human Genetic Variation



A graphical representation of the normal human karyotype

Human genetic variation refers to genetic differences both within and among populations. There may be multiple variants of any given gene in the human population (alleles), leading to polymorphism. Many genes are not polymorphic, meaning that only a single allele is present in the population: that allele is then said to be fixed.

No two humans are genetically identical. Even monozygotic twins, who develop from one zygote, have infrequent genetic differences due to mutations occurring during development and gene copy number variation has been observed. Differences between individuals, even closely related individuals, are the key to techniques such as genetic fingerprinting. Alleles occur at different frequencies in different human populations, with populations that are more geographically and ancestrally remote tending to differ more.

Causes of differences between individuals include the exchange of genes during meiosis and various mutational events. There are at least two reasons why genetic variation exists between populations. Natural selection may confer an adaptive advantage to individuals in a specific environment if an allele provides a competitive advantage. Alleles under selection are likely to occur only in those geographic regions where they confer an advantage. The second main cause of genetic variation is due to the high degree of neutrality of most mutations. Most mutations do not appear to have any selective effect one way or the other on the organism. The main cause is genetic drift, this is the effect of random changes in the gene pool. In humans, founder effect and past small population size (increasing the likelihood of genetic drift) may have had an important influence in neutral differences between populations.

The theory that humans recently migrated out of Africa is sometimes given as an example of this. It has been theorized that the population which migrated out of Africa only represented a small fraction of the genetic variation in Africa, and that this is a contributing cause of the observed lower levels of diversity in all indigenous humans outside of Africa. Generally, more recent neutral polymorphisms caused by mutation are likely to be relatively geographically localized and rare, while older polymorphisms are more likely to be shared by a wider range of human groups. The large majority of observed genetic variation occurs within a population in any geographic region and not between populations in different regions, although it is still usually possible to accurately identify the geographic origins of any individual's ancestors by genetic means.

The study of human genetic variation has both evolutionary significance and medical applications. The study can help scientists understand ancient human population migrations as well as how different human groups are biologically related to one another. From a medical perspective the study of human genetic variation may be important because some disease causing alleles occur at a greater frequency in people from specific geographic regions.

Genetic variation

Genetic variation, variation in alleles of genes, occurs both within and among populations. Genetic variation is important because it provides the “raw material” for natural selection.

Measures of variation

"Genetic variation among individual humans occurs on many different scales, ranging from gross alterations in the human karyotype to single nucleotide changes."

Single nucleotide polymorphisms



DNA molecule 1 differs from DNA molecule 2 at a single base-pair location (a C/T polymorphism).

Nucleotide diversity is based on single mutations called single nucleotide polymorphisms (SNPs). The nucleotide diversity between humans is about 0.1%, which is 1 difference per 1,000 base pairs. A difference of 1 in 1,000 nucleotides between two humans chosen at random amounts to approximately 3 million nucleotide differences since the human genome has about 3 billion nucleotides. Most of these SNPs are neutral but some are functional and influence phenotypic differences between humans through alleles. It is estimated that a total of 10 million SNPs exist in the human population of which at least 1% are functional.

Copy number variation

More recently a better understanding of the structure of the genome has been gained with the publication of two examples of full sequences of an individual's genome. This represents a new development because the Human Genome Project and a parallel project by Celera Genomics produced two haploid sequences, both of which were an amalgamation of sequences from many individuals. Recently the diploid sequences of both Craig Venter and James Watson have been published. Analysis of diploid sequences has shown that non-SNP variation accounts for much more human genetic variation than single nucleotide diversity. This non-SNP variation includes copy number variation and results from deletions, inversions, insertions and duplications. It is estimated that approximately 0.4% of the genomes of unrelated people typically differ with respect to copy number. When copy number variation is included, human to human genetic variation is estimated to be at least 0.5% (99.5% similarity). Copy number variations are inherited but can also arise during development.

Epigenetics

Epigenetics is another type of genetic variation. "This type of variation arises from chemical tags that attach to DNA and affect how it gets read. The chemical tags, called epigenetic markings, act as switches that control how genes can be read." At some alleles, the epigenetic state of the DNA, and associated phenotype, can be inherited transgenerationally.

Genetic variability

Genetic variability is a measure of the tendency of individual genotypes in a population to vary (become different) from one another. Variability is different from genetic diversity, which is the amount of variation seen in a particular population. The variability of a trait describes how much that trait tends to vary in response to environmental and genetic influences.

Clines

In biology, a cline is a term used to describe a continuum of species, populations, races, varieties, or forms of organisms that exhibit gradual phenotypic and/or genetic differences over a geographical area, typically as a result of environmental heterogeneity.

In the scientific study of human genetic variation, a gene cline can be rigorously defined and subjected to quantitative metrics.

Haplogroups

In the study of molecular evolution, a haplogroup is a group of similar haplotypes that share a common ancestor with a single nucleotide polymorphism (SNP) mutation. Haplogroups pertain to deep ancestral origins dating back thousands of years.

In human genetics, the haplogroups most commonly studied are Y-chromosome (Y-DNA) haplogroups and mitochondrial DNA (mtDNA) haplogroups, both of which can be used to define genetic populations. Y-DNA is passed solely along the patrilineal line, from father to son, while mtDNA is passed down the matrilineal line, from mother to both daughter and son. The Y-DNA and mtDNA may change by chance mutation at each generation.

Variable number tandem repeats

A variable number tandem repeat (VNTR) is a location in a genome where a short nucleotide sequence is organized as a tandem repeat. These can be found on many chromosomes, and often show variations in length between individuals. Each variant acts as an inherited allele, allowing them to be used for personal or parental identification. Their analysis is useful in genetics and biology research, forensics, and DNA fingerprinting.

There are two principal families of VNTRs: microsatellites and minisatellites. The former are repeats of sequences less than about 5 base pairs in length, while the latter involve longer blocks.

History and geographic distribution



Map of the migration of modern humans out of Africa, based on mitochondrial DNA. Colored rings indicate thousand years before present.

A 10-year study published in 2009 analyzed the patterns of variation at 1,327 DNA markers of 121 African populations, 4 African American populations, and 60 non-African populations. The research showed that there is more human genetic diversity in Africa than anywhere else on Earth. The genetic structure of Africans was traced to 14 ancestral population clusters and the ancestral origin of humans was determined to probably be located in southern Africa, near the border of Namibia and South Africa.

Human genetic diversity decreases in native populations with migratory distance from Africa and this is thought to be the result of bottlenecks during human migration, which are events that temporarily reduce population size. It has been shown that variations in skull measurements decrease with distance from Africa at the same rate as the decrease in genetic diversity. These data support the Out of Africa theory over the multiregional origin of modern humans hypothesis. The aforementioned April 2009 study identifies the likely origin of modern human migration as being in southwestern Africa, near the coastal border of Namibia and Angola, and the exit point out of Africa as being in East Africa.

The *recent African origin of modern humans* is the mainstream model describing the origin and early dispersal of anatomically modern humans, *Homo sapiens sapiens*. The

theory is known popularly as the *(Recent) Out-of-Africa* model. The hypothesis originated in the 19th century, with Darwin's *Descent of Man*, but remained speculative until the 1980s when it was corroborated based on a study of present-day mitochondrial DNA, combined with evidence based on physical anthropology of archaic specimens.

According to both genetic and fossil evidence, archaic Homo sapiens evolved to anatomically modern humans solely in Africa, between 200,000 and 100,000 years ago, with members of one branch leaving Africa by 60,000 years ago and over time replacing earlier human populations such as Neanderthals and *Homo erectus*. According to this theory, around the above time frame, one of the African subpopulations went through a process of speciation prohibiting gene flow between African and Eurasian Human populations.

Population genetics

In the field of population genetics, it is believed that the distribution of neutral polymorphisms among contemporary humans reflects human demographic history. It is believed that humans passed through a population bottleneck before a rapid expansion coinciding with migrations out of Africa leading to an African-Eurasian divergence around 100,000 years ago (ca. 5,000 generations), followed by a European-Asian divergence about 40,000 years ago (ca. 2,000 generations). Richard G. Klein, Nicholas Wade and Spencer Wells, among others, have postulated that modern humans did not leave Africa and successfully colonize the rest of the world until as recently as 60,000 - 50,000 years B.P., pushing back the dates for subsequent population splits as well.

The rapid expansion of a previously small population has two important effects on the distribution of genetic variation. First, the so-called founder effect occurs when founder populations bring only a subset of the genetic variation from their ancestral population. Second, as founders become more geographically separated, the probability that two individuals from different founder populations will mate becomes smaller. The effect of this assortative mating is to reduce gene flow between geographical groups, and to increase the genetic distance between groups. The expansion of humans from Africa affected the distribution of genetic variation in two other ways. First, smaller (founder) populations experience greater genetic drift because of increased fluctuations in neutral polymorphisms. Second, new polymorphisms that arose in one group were less likely to be transmitted to other groups as gene flow was restricted.

Our history as a species also has left genetic signals in regional populations. For example, in addition to having higher levels of genetic diversity, populations in Africa tend to have lower amounts of linkage disequilibrium than do populations outside Africa, partly because of the larger size of human populations in Africa over the course of human history and partly because the number of modern humans who left Africa to colonize the rest of the world appears to have been relatively low (Gabriel *et al.* 2002). In contrast, populations that have undergone dramatic size reductions or rapid expansions in the past and populations formed by the mixture of previously separate ancestral groups can have unusually high levels of linkage disequilibrium (Nordborg and Tavare 2002).

Many other geographic, climatic, and historical factors have contributed to the patterns of human genetic variation seen in the world today. For example, population processes associated with colonization, periods of geographic isolation, socially reinforced endogamy, and natural selection all have affected allele frequencies in certain populations (Jorde *et al.* 2000b; Bamshad and Wooding 2003). In general, however, the recency of our common ancestry and continual gene flow among human groups have limited genetic differentiation in our species.

Distribution of variation

The distribution of genetic variants within and among human populations are impossible to describe succinctly because of the difficulty of defining a "population," the clinal nature of variation, and heterogeneity across the genome (Long and Kittles 2003). In general, however, an average of 85% of genetic variation exists within local populations, ~7% is between local populations within the same continent, and ~8% of variation occurs between large groups living on different continents,. (Lewontin 1972; Jorde *et al.* 2000a; Hinds *et al.* 2005). The recent African origin theory for humans would predict that in Africa there exists a great deal more diversity than elsewhere, and that diversity should decrease the further from Africa a population is sampled. Long and Kittles show that indeed, African populations contain about 100% of human genetic diversity, whereas in populations outside of Africa diversity is much reduced, for example in their population from New Guinea only about 70% of human variation is captured.

Phenotypic variation

Faces show phenotypic variation. Some of this is caused by genetic variation.

Sub-Saharan Africa has the most human genetic diversity and the same has been shown to hold true for phenotypic diversity. Phenotype is connected to genotype through gene expression. Genetic diversity decreases smoothly with migratory distance from that region, which many scientists believe to be the origin of modern humans, and that decrease is mirrored by a decrease in phenotypic variation. Skull measurements are an example of a physical attribute whose within-population variation decreases with distance from Africa.

The distribution of many physical traits resembles the distribution of genetic variation within and between human populations (American Association of Physical Anthropologists 1996; Keita and Kittles 1997). For example, ~90% of the variation in human head shapes occurs within continental groups, and ~10% separates groups, with a greater variability of head shape among individuals with recent African ancestors (Relethford 2002).

A prominent exception to the common distribution of physical characteristics within and among groups is skin color. Approximately 10% of the variance in skin color occurs within groups, and ~90% occurs between groups (Relethford 2002). This distribution of skin color and its geographic patterning — with people whose ancestors lived predominantly near the equator having darker skin than those with ancestors who lived predominantly in higher latitudes — indicate that this attribute has been under strong selective pressure. Darker skin appears to be strongly selected for in equatorial regions to prevent sunburn, skin cancer, the photolysis of folate, and damage to sweat glands (Sturm *et al.* 2001; Rees 2003).

A study published in 2007 found that 25% of genes showed different levels of gene expression between populations of European and Asian descent. The primary cause of this difference in gene expression was thought to be SNPs in gene regulatory regions of DNA. Another study published in 2007 found that approximately 83% of genes were expressed at different levels among individuals and about 17% between populations of European and African descent.

Archaic admixture

Interbreeding of Neanderthals and anatomically modern humans during the Middle Paleolithic is a hypothesis. In May 2010, the Neanderthal Genome Project presented genetic evidence that interbreeding did likely take place and that a small but significant portion of Neanderthal admixture is present in the DNA of modern non-African populations.

In December 2010, a study found that between 4% and 6% of the genome of Melanesians (represented by the Papua New Guinean and Bougainville Islander) derives from Denisova hominin - a previously unknown species, which shares common origin with Neanderthals.It was possibly introduced during the early migration of the ancestors of Melanesians into Southeast Asia. This history of interaction suggests that Denisovans once ranged widely over eastern Asia.

Melanesians thus emerge as the most archaic-admixed population, having Denisovan/Neandertal-related admixture of ~8%.

Categorization of the world population



Chart showing human genetic clustering.

New data on human genetic variation has reignited the debate surrounding race. Most of the controversy surrounds the question of how to interpret this new data and whether conclusions based on existing data are sound. A large majority of researchers endorse the view that continental groups do not constitute different subspecies. However, other researchers still debate whether evolutionary lineages should rightly be called "races". These questions are particularly pressing for ancestry related health issues, where self-identified race is often used as an indicator of ancestry.

Although the genetic differences among human groups are relatively small, these differences in certain genes such as duffy, ABCC11, SLC24A5, called ancestry-informative markers (AIMs) nevertheless can be used to reliably situate many individuals within broad, geographically based groupings or self-identified race. For example, computer analyses of hundreds of polymorphic loci sampled in globally distributed populations have revealed the existence of genetic clustering that roughly is associated with groups that historically have occupied large continental and subcontinental regions.

Some commentators have argued that these patterns of variation provide a biological justification for the use of traditional racial categories. They argue that the continental clusterings correspond roughly with the division of human beings into sub-Saharan Africans; Europeans, Western Asians, Central Asians, Southern Asians and Northern Africans; Eastern Asians, Southeast Asians, Polynesians and Native Americans; and other inhabitants of Oceania (Melanesians, Micronesians & Australian Aborigines) (Risch *et al.* 2002). Other observers disagree, saying that the same data undercut traditional notions of racial groups (King and Motulsky 2002; Calafell 2003; Tishkoff and Kidd 2004). They point out, for example, that major populations considered races or subgroups within races do not necessarily form their own clusters.

Furthermore, because human genetic variation is clinal, many individuals affiliate with two or more continental groups. Thus, the genetically based "biogeographical ancestry" assigned to any given person generally will be broadly distributed and will be accompanied by sizable uncertainties (Pfaff *et al.* 2004).

In many parts of the world, groups have mixed in such a way that many individuals have relatively recent ancestors from widely separated regions. Although genetic analyses of large numbers of loci can produce estimates of the percentage of a person's ancestors coming from various continental populations (Shriver *et al.* 2003; Bamshad *et al.* 2004), these estimates may assume a false distinctiveness of the parental populations, since human groups have exchanged mates from local to continental scales throughout history (Cavalli-Sforza *et al.* 1994; Hoerder 2002). Even with large numbers of markers, information for estimating admixture proportions of individuals or groups is limited, and estimates typically will have wide confidence intervals (Pfaff *et al.* 2004).

Lewontin's Fallacy

In 2003 A. W. F. Edwards wrote a paper called Lewontin's Fallacy, rebutting the argument that because most genetic variation is within-group, classification of humans is not possible. He claimed that this conclusion ignores the fact that most of the information that distinguishes populations is hidden in the correlation structure of the data and not simply in the variation of the individual factors. Edwards concludes that "It is not true that 'racial classification is ... of virtually no genetic or taxonomic significance' or that 'you can't predict someone’s race by their genes'." Undeterred, in an article titled "Confusions About Human Races" published in 2006, Lewontin maintains that race is no more than a social construct.

Genetic clustering

Genetic data can be used to infer population structure and assign individuals to groups that often correspond with their self-identified geographical ancestry. Recently, Lynn Jorde and Steven Wooding argued that "Analysis of many loci now yields reasonably accurate estimates of genetic similarity among individuals, rather than populations. Clustering of individuals is correlated with geographic origin or ancestry."

Forensic anthropology

Forensic anthropologists can determine race (e.g. Asian, African, or European ancestry) from skeletal remains with a high degree of accuracy by conducting bone analysis. Studies have shown that individual test methods such as midfacial measurements and femur traits can be over 80 percent accurate, and in combination can achieve very high levels of accuracy. The skeletons of mixed-race individuals can, however, exhibit characteristics of more than one racial group. Despite the success of this method with the remains of individuals with ancestry predominantly from a single race, anthropologists, including George W. Gill and C. Loring Brace, disagree on whether race is a valid biological concept.



Triangle plot shows average admixture of five North American ethnic groups. Individuals that self-identify with each group can be found at many locations on the map, but on average groups tend to cluster differently.

Admixture

Miscegenation between two populations reduces the average genetic distance between the populations. During the Age of Discovery which began in the early 15th century, European explorers sailed all around the globe, reaching all the major continents. In the process they came into contact with many populations that had been isolated for thousands of years. It is generally accepted that the Tasmanian aboriginals were the most isolated group on the planet. They were driven to extinction by European explorers, however a number of their descendants survive today as a result of admixture with Europeans. This is an example of how modern migrations have begun to reduce the genetic divergence of the human race.

The demographic composition of the old world has not changed significantly since the age of discovery. However new world demographics were radically changed within a short time following the voyage of Columbus. The colonization of the Americas brought Native Americans into contact with the distant populations of Europe, Africa, and Asia. As a result many countries in the Americas have significant and complex multiracial populations. Furthermore many who identify themselves by only one race still have multiracial ancestry.

Health

Differences in allele frequencies contribute to group differences in the incidence of some monogenic diseases, and they may contribute to differences in the incidence of some common diseases (Risch *et al.* 2002; Burchard *et al.* 2003; Tate and Goldstein 2004). For the monogenic diseases, the frequency of causative alleles usually correlates best with ancestry, whether familial (for example, Ellis-van Creveld syndrome among the Pennsylvania Amish), ethnic (Tay-Sachs disease among Ashkenazi Jewish populations), or geographical (hemoglobinopathies among people with ancestors who lived in malarial regions). To the extent that ancestry corresponds with racial or ethnic groups or subgroups, the incidence of monogenic diseases can differ between groups categorized by race or ethnicity, and health-care professionals typically take these patterns into account in making diagnoses.

Even with common diseases involving numerous genetic variants and environmental factors, investigators point to evidence suggesting the involvement of differentially distributed alleles with small to moderate effects. Frequently cited examples include hypertension (Douglas *et al.* 1996), diabetes (Gower *et al.* 2003), obesity (Fernandez *et al.* 2003), and prostate cancer (Platz *et al.* 2000). However, in none of these cases has allelic variation in a susceptibility gene been shown to account for a significant fraction of the difference in disease prevalence among groups, and the role of genetic factors in generating these differences remains uncertain (Mountain and Risch 2004).

Neil Risch of Stanford University has proposed that self-identified race/ethnic group could be a valid means of categorization in the USA for public health and policy considerations. While a 2002 paper by Noah Rosenberg's group makes a similar claim

"The structure of human populations is relevant in various epidemiological contexts. As a result of variation in frequencies of both genetic and nongenetic risk factors, rates of disease and of such phenotypes as adverse drug response vary across populations. Further, information about a patient's population of origin might provide health care practitioners with information about risk when direct causes of disease are unknown."

Genome projects

Human genome projects are scientific endeavors that determine or study the structure of the human genome. The Human Genome Project was a landmark genome project.

Chapter- 9

Human Genetic Engineering

Human genetic engineering is the alteration of an individual's genotype with the aim of choosing the phenotype of a newborn or changing the existing phenotype of a child or adult. It holds the promise of curing genetic diseases like cystic fibrosis, and increasing the immunity of people to viruses. It is speculated that genetic engineering could be used to change physical appearance, metabolism, and even improve mental faculties like memory and intelligence, although for now these uses seem to be of lower priority to researchers and are therefore limited to science fiction.

History

The first gene therapy trials on humans began in 1990 on patients with Severe Combined Immunodeficiency (SCID). In 2000, the first gene therapy "success" resulted in SCID patients with a functional immune system. These trials were stopped when it was discovered that two of ten patients in one trial had developed leukemia resulting from the insertion of the gene-carrying retrovirus near an oncogene. In 2007, four of the ten patients had developed leukemia. Work is now focusing on correcting the gene without triggering an oncogene.

Trial treatments of SCID have been gene therapy's only success; since 1999, gene therapy has restored the immune systems of at least 17 children with two forms (ADA-SCID and X-SCID) of the disorder.

Human genetic engineering is already being used on a small scale to allow infertile women with genetic defects in their mitochondria to have children. Healthy human eggs from a second mother are used. The child produced this way has genetic information from two mothers and one father. The changes made are germline changes and will likely be passed down from generation to generation, and, thus, are a permanent change to the human genome.

Other forms of human genetic engineering are still theoretical. Recombinant DNA research is usually performed to study gene expression and various human diseases. Some drastic demonstrations of gene modification have been made with mice and other

animals, however, testing on humans is generally considered off-limits. In some instances changes are usually brought about by removing genetic material from one organism and transferring them into another species.

Methods

Somatic

Somatic genetic engineering involves adding genes to cells other than egg or sperm cells. For example, if a person had a disease caused by a defective gene, a healthy gene could be added to the affected cells to treat the disorder. As of now, this is likely to take the form of gene therapy. The distinguishing characteristic of somatic engineering is that it is non-inheritable, i.e. the new gene would not be passed to the recipient's offspring.

There are two techniques researchers are currently experimenting with:

- Viruses are good at injecting their DNA payload into human cells and reproducing it. By adding the desired DNA to the DNA of non-pathogenic virus, a small amount of virus will reproduce the desired DNA and spread it all over the body.
- Manufacture large quantities of DNA, and somehow package it to induce the target cells to accept it, either as an addition to one of the original 23 chromosomes, or as an independent 24th human artificial chromosome.

Germline

Germline engineering involves changing genes in eggs, sperm, or very early embryos. This type of engineering is inheritable, meaning that the modified genes would appear not only in offspring that resulted from the procedure, but also in subsequent generations.

Uses

Two motivators of human genetic engineering are referred to as "negative" and "positive". The former aims to remove genetic disorders and the latter aims to alter phenotypic expression to result in an enhanced being.

Negative genetic engineering (cures and treatments)

When treating problems that arise from genetic disorder, one solution is gene therapy, also known as negative genetic engineering. A genetic disorder is a condition caused by the genetic code of the individual, such as spina bifida or autism. When this happens, genes may be expressed in unfavorable ways or not at all, and this generally leads to further complications.

The idea of gene therapy is that a non-pathogenic virus or other delivery systems can be used to insert into DNA—a good copy of the gene—into cells of the living individual.

The modified cells would divide as normal and each division would produce cells that express the desired trait. The result would be that he/she would then have the ability to express the trait that was previously absent, at least partially. This form of genetic engineering could help alleviate many problems, such as diabetes, cystic fibrosis, or other genetic diseases.

Positive genetic engineering (enhancement)

The potential of genetic engineering to cure medical conditions opens the question of exactly what such a condition is. Some view aging and death as medical conditions and therefore potential targets for engineering solutions. They see human genetic engineering potentially as a key tool in this. The difference between cure and enhancement from this perspective is merely one of degree. Theoretically genetic engineering could be used to drastically change people's genomes, which could enable people to regrow limbs and other organs, perhaps even extremely complex ones such as the spine.

It could also be used to make people smarter, stronger, or to increase the capacity of the lungs, among other things. If a gene exists in nature, perhaps it could be changed into a human cell. In this view, there is no qualitative difference (only a quantitative one) between, for instance, a genetic intervention to cure muscular atrophy, and a genetic intervention to improve muscle function even when those muscles are functioning at or below the human average (since there is also an average muscle function for those with a particular type of dystrophy, which the treatment would improve upon).

Others feel, there is an important distinction between using genetic technologies to treat those who are suffering, and to make those who are already healthy seem more superior to the average person. Though theory and speculation suggest, that genetic engineering could be used to make people stronger, faster, smarter, or to increase lung capacity. The AAAS report finds that there is little evidence to support this theory. Can this currently be done without very unsafe and therefore unethical human experiments. Because different cells have different tasks, changing one cell to do a function differently, will not only affect that one task, but it can affect many other tasks as well.

Controversy

Ethics

The genetic engineering of humans has raised many controversial ethical issues. While negative genetic engineering (gene therapy) does indeed raise a debate, the use of genetic engineering for human enhancement arouses the strongest feelings on both sides.

Genetic engineering is tested on animals, often including primates. Some animal rights activists find this inhumane.

Genetic engineering must be used to cure peoples with diabetes. It is possible to extract genes from cells which are called beta cells and then to insert the insulin producing genes

into a bacterium. Then the bacterium will star producing insulin. Genetic modification of embryos can pose an ethical question about the rights of the baby. One belief is that every fetus should be free to not be genetically modified. Others believe that parents hold the rights to change their unborn children. Still others believe that every child should have the right to be born free from preventable diseases.

Molecular Biologist Lee M. Silver believes that unlike Aldous Huxley's Brave New World, where a totalitarian government controls all of the genetic enhancements (they actually use eugenics instead of direct genetic modification) in society, the use of gene therapy to design children will be spread through what he calls "free market eugenics" (Silver 315). Wealthy families will opt to design their child with genetic advantages because other families are doing so, and everybody wants to provide their newborn child with the best opportunities in life, with a leg up on the competition.

The greatest fear for Silver is that we will design so many children with germline gene therapy, that the families wealthy enough to design their children, will pass down these enhanced traits to future generations. This gene therapy will obviously cost money, and the less wealthy families will be left to procreate naturally, and introduce their children into the world disadvantaged from their first breath.

The impact on society will be a new alignment of classes, no longer will we separate people by their ethnic differences, the new division will be between what Silver calls 'the naturals' and 'the GenRich', or genetically enhanced. The major worry here is that the 'genetic gulf' between these two classes will become so wide that humans will become separate species (Silver 313).

Chapter- 10

Human Skin Color

Human skin color is primarily due to *melanin*; it ranges from skin almost black in appearance to white with a pinkish tinge due to blood vessels underneath. Variations in skin hue can be caused by tanning due to exposure to sunlight, but are mainly of genetic origin although the evolutionary causes are not completely certain. The leading explanation is that skin colour adapts to sunlight intensities which produce vitamin D deficiency or ultraviolet light damage to folic acid. Other hypotheses include protection from ambient temperature, infections, skin cancer or frostbite, an alteration in food, and sexual selection. According to scientific studies, natural human skin color diversity is highest in Sub-Saharan African populations, with skin reflectance values ranging from 19 to 46 (med. 31) compared with European and East Asian populations which have skin reflectance values of 62 to 69 and 50 to 59 respectively.

Melanin and genes

Melanin comes in two types: pheomelanin (red) and eumelanin (very dark brown). Both the amount and type of melanin produced is controlled by a number of genes which operate under incomplete dominance. One copy of each of the various genes is inherited from each parent. Each gene can come in several alleles, resulting in the great variety of human skin tones. By absorbing ultraviolet (UV) radiation from the sun, melanin controls the amount that penetrates the skin. UV radiation is needed to manufacture vitamin D, but excess UV can damage health.

Genetics of skin color variation

The KIT ligand (KITLG) gene is involved in the permanent survival, proliferation and migration of melanocytes, the cells that produce melanin. A mutation of this gene, *A326G* (rs642742) has been positively associated with variations of skin colour in African-Americans of mixed West African and European descent and is estimated to account for 15-20% of the melanin difference between African and non-African populations. The *A326G* allele occurs in over 80% of European and Asian samples, compared with less than 10% in African samples.

Agouti signalling peptide (ASIP) acts as an inverse agonist, binding in place of alpha-MSH and thus inhibiting eumelanin production. Studies have found alleles in the vicinity of *ASIP* are associated with skin colour in humans - rs2424984 has been identified as one of three indicators of skin tone in a forensics analysis of human phenotypes and has a frequency of roughly 80% in Europeans, 75% in Asians and 20-25% in Africans. A 2-SNP haplotype (rs4911414 and rs1015362) has also been linked with skin colour variation within European populations and has a similar frequency distribution.

Solute carrier family 24 member 5 (SLC24A5) regulates calcium in melanocytes and is important in the process of melanogenesis. The *Thr111Ala* allele (rs1426654) has been shown to be a major factor in the light skin tone of Europeans in a number of studies. It is virtually non-existant in Asian and African populations and is found in nearly 100% of Europeans. It is believed to represent some 25-40% of the difference in skin tone between Europeans and Africans, and appears to have arisen as recently as within the last 10,000 years.

Solute carrier family 45 member 2 (SLC45A2 or MATP) aids in the transport and processing of tyrosine, a precursor to melanin. It has also been shown to be a major factor in the skin colour of modern Europeans through its *Phe374Leu* (rs16891982) variation.. Like *SLC24A5* it is ubiquitous in European populations but extremely rare elsewhere.

The TYR gene encodes the enzyme tyrosinase which is involved in the production of melanin from tyrosine. It has an allele, *Ser192Tyr* (rs1042602), found solely in 40-50% of Europeans and linked to light coloured skin in studies of mixed-race populations.

A number of studies have found a genes linked to human skin pigmentation that have alleles with statistically significant frequencies in Asian populations. While not linked to measurements of skin tone variation directly, dopachrome tautomerase (DCT or TYRP2 rs2031526), melanocortin 1 receptor (MC1R) *Arg163Gln* (rs885479) and attractin (ATRN) have been indicated as possible sources for the evolution of light skin in East Asian populations.

Mutations in genes can cause also affect skin colour through oculocutaneous albinism (OCA) - a lack of pigment in the eyes, skin and sometimes hair that occurs occasionally in a very small fraction of the population. The four known types of *OCA* are caused by mutations of the *TYR*, OCA2, TYRP1 and *SLC45A2* genes.

The gene MC1R is primarily responsible for determining whether pheomelanin and eumelanin is produced in humans. Mutations of this very polymorphic gene, such as *Arg151Sys* (rs1805007), *Arg160Trp* (rs1805008), *Asp294Sys* (rs1805009), *Val60Leu* (rs1805005) and *Val92Met* (rs2228479) have been shown to cause red hair and pale skin that does not tan in a small percentage of the human population. Although these alleles have differing frequencies across African, European and Asian populations, there is no evidence of positive selection for them and they do not appear to be associated with the evolution of lighter skin in Eurasian populations.

Evolution of skin color

Rogers *et al.* (2004) performed an examination of the variation in MC1R nucleotide sequences for people of different ancestry and compared the sequences for chimpanzees and humans from various regions of the Earth. Rogers concluded that roughly five million years ago, at the time of the evolutionary separation of chimpanzees and humans, the common ancestors of all humans had light skin that was covered by dark hair. Over time the hair disappeared to allow better heat dissipation through sweating and the skin tone grew darker to protect from folate depletion to the increased exposure to sunlight. By 1.2 million years ago, shortly after the final speciation of homo sapiens from homo ergaster, the ancestors of all people living today had exactly the same receptor protein as modern Africans. Evolutionary pressure meant that any gene variations that resulted in lighter skin were unable to survive under the intense African sun, and human skin remained dark for the next 1.1 million years.

Approximately 70,000-100,000 years ago modern humans began to migrate away from the tropics to the north where they were exposed to less intense sunlight, possibly in part due to the need for greater use of clothing to protect against the colder climate. Under these conditions there was less photodestruction of folate and so the evolutionary pressure stopping lighter-skinned gene variants from surviving was reduced. In addition, lighter skin is able to generate more vitamin D (cholecalciferol) than darker skin so would have represented a health benefit in reduced sunlight if there were limited sources of vitamin D. Hence the leading hypothesis for the evolution of human skin color proposes that:-

1. From ~1.2 million years ago to less than 100,000 years ago, the ancestors of all people alive were as dark as modern Africans.
2. As populations began to migrate, the evolutionary constraint keeping skin dark decreased proportionally to the distance North a population migrated, resulting in a range of skin tones within northern populations.
3. As some point northern populations experienced positive selection for lighter skin due to the increased production of vitamin D from sunlight and the genes for darker skin disappeared from these populations.

The genetic mutations leading to light skin, though different among East Asians and Europeans, suggest the two groups experienced a similar selective pressure due to settlement in northern latitudes.

There is a long-standing hypothesis that the selection for lighter skin due to higher vitamin D absorption occurred soon after the Out of Africa migration sometime before 40,000 years ago. A number of researchers disagree with this and suggest that the northern latitudes permitted enough synthesis of vitamin D combined with food sources from hunting to keep populations healthy, and only when agriculture was adopted was there a need for lighter skin to maximize the synthesis of vitamin D. The theory suggests that the reduction of game meat, fish, and some plants from the diet resulted in skin turning white many thousands of years after settlement in Europe and Asia. This theory is

supported by a study into the SLC24A5 gene which found that the allelle associated with light skin in Europe may have originated as recently as 6,000-10,000 years ago which is in line with the earliest evidence of farming.

Health related effects

Dark skin with large concentrations of melanin protects against exposure to ultraviolet light and skin cancers; light-skinned persons have about a tenfold greater risk of dying from skin cancer, compared with dark-skinned persons, under equal sunlight exposure. Furthermore, UV-A rays from sunlight are believed to interact with folic acid in ways which may damage health. In a wide range of traditional societies the sun was avoided as far as possible, especially around noon when the ultraviolet radiation in sunlight is at its most intense. Midday was a time when people stayed in the shade and had the main meal followed by a nap. While dark skin offers superior protection from intense ultraviolet light, it may be the cause of low Vitamin D levels in African Americans and has led to concern that darker skinned people, such as African Americans, living at relatively high latitude may be having inadequate vitamin D levels because of their relatively greater pigmentation. Research shows that dark-skinned people living in Western societies have lower vitamin D levels. The explanation for low vitamin D levels in dark-skinned people is thought to be that melanin in the skin hinders vitamin D synthesis, however recent studies have found novel evidence that low vitamin D levels among people of African ancestry may be due to other reasons, that black women have an increase in serum parathyroid hormone - implicated in adverse cardiovascular outcomes - at a lower vitamin D level than white women, and in a large scale association study of the genetic determinants of vitamin D insufficiency in Caucasians no links to pigmentation were found.

Cultural effects

French actresses Romane Bohringer and Aïssa Maïga at the Deauville American Film Festival, 2009

Differences in skin tone are the most readily perceptible phenotypical distinction of human populations, however the connotations associated with dark and light skin have varied across cultures and time.

A number of indigenous African groups, such as the Maasai, associated pale skin with being cursed or caused by evil spirits associated with witch craft. They would abandon their children born with conditions such as albinism and showed a sexual preference for darker skin.

Before the Industrial Revolution in Europe, pale skin was a sign of high social status. The poorer classes worked outdoors and got darker skin from exposure to the Sun, while the

upper class stayed indoors and had light skin. Light skin became associated with wealth and high position.

According to classical scholar Frank Snowden, the ancient Egyptians and Greeks assigned relatively neutral connotations to skin color variation. This was because conquest rather than skin color was the major determinant of slave status.

Colonisation and slavery by European countries led to a belief that dark skin was uncivilised and was to be considered inferior and subordinate to lighter skin, a belief that has continued into modern times for many people. During slavery, lighter-skinned African Americans were perceived as more intelligent, cooperative, and beautiful. They were more likely to work as house slaves and were also given preferential treatment by plantation owners and their henchmen. For example, they had a chance to get an education while darker African Americans worked in the fields and did not get an education.

These racial stereotypes about worth and beauty were still persistent in the last half of the 20th century; the African American journalist Jill Nelson wrote that "to be both prettiest and black was impossible" and elaborated:

As a girl and young woman, hair, body, and color were society's trinity in determining female beauty and identity, the cultural and value-laden gang of three that formed the boundaries and determined the extent of women's visibility, influence, and importance. For the most part, they still are. We learn as girls that in ways both subtle and obvious, personal and political, our value as females is largely determined by how we look. As we enter womanhood, the pervasive power of this trinity is demonstrated again and again in how we are treated by the men we meet, the men we work for, the men who wield power, how we treat each other and, most of all, ourselves. For black women, the domination of physical aspects of beauty in women's definition and value render us invisible, partially erased, or obsessed, sometimes for a lifetime, since most of us lack the major talismans of Western beauty. Black women find themselves involved in a lifelong effort to self-define in a culture that provides them no positive reflection.

With the majority of Western mass media and popular culture reinforcing negative stereotypes about dark skin, light skin has become a symbol of wealth and success through much of the developing world. Skin whitening products sales grew from $40 to $43 billion in 2008. Skin whitening is not uncommon in Africa and several research projects have suggested a general preference for lighter-skinned women by African-American men.

Lighter skin is seen as more attractive in Latin America. In Mexico and in Brazil, light skin represents power, as well as attractiveness. A dark-skinned person is more likely to be discriminated against in Brazil. Most South American actors and actresses (as do most other Latin American actors and actresses) have Nordic features - blue eyes, pale skin, and blond hair. A light-skinned person is considered to be more privileged and have a higher social status; a person with light skin is considered more beautiful and it means

that the person has more wealth. Skin color is such an obsession in these countries that specific words describe distinct skin tones from "*hincha*", Puerto Rican slang for "glass of milk" to "*morena*", literally "brown".

A Vietnamese motorcyclist wears long gloves to block the sun, despite the tropical heat.

In South and East Asian countries, light skin has traditionally been seen as more attractive and a preference for lighter skin remains prevalent. In ancient China and Japan, for example, pale skin can be traced back to ancient drawings depicting women and goddesses with fair skin tones. In ancient China, Japan, and Southeast Asia, pale skin was seen as a sign of wealth. Thus, skin whitening cosmetic products are popular in East Asia. 4 out of 10 women surveyed in Hong Kong, Malaysia, the Philippines and South Korea used a skin-whitening cream, and more than 60 companies globally compete for Asia's estimated $18 billion market. Changes in regulations in the cosmetic industry led to skin care companies like Super Skin Lightener introducing harm free skin lighteners. In India also, pale skin is considered more attractive and skin whitening is prevalent. Most actors and actresses have light skin.

It has been found that, on average, women of a given ancestry have a lighter skin tone than men of the same ancestry and that there is a sexual preference for paleness in women and darkness in men in many cultures throughout the world. In his foreword to Peter Frost's 2005 *Fair Women, Dark Men*, U. of Washington sociologist Pierre L. van den Berghe summarizes:

"Although virtually all cultures express a marked preference for fair female skin, even those with little or no exposure to European imperialism, and even those whose members

are heavily pigmented, the trend ... in integrated societies has [been toward] increasing popularity for men of color, especially those [of] African descent. These trends have been recorded in areas such as South America, where in Brazil it was estimated that by 2009 black people of African descent will be the single most dominant ethnic group. In popular media in the western world 'blacks' have been repeatedly surrounded by advantageous stereotypes and myths that praise their athletic aptitudes amongst many other things, and often depict them as males of superior genetic inheritance."

In modern Western societies darker skin is becoming more desirable in both men and women. Pale skin has become associated with indoor office workers, while tanned skin shows the increased leisure time, sportiness and good health that comes with wealth and higher social status. A preference for women with tanned skin has emerged with studies find that the degree of tanning is directly related to how attractive a young woman is perceived to be. The election of a dark-skinned US President and the financial success of many African-American singers and actors has lead to a number of positive stereotypes associated with darker skin tone, and an increase in the perceived attractiveness of dark-skinned women.

Tanning

At the beginning of the 20th Century, in the United States, lighter-skinned people avoided the sun. Tanned skin was considered lower class, a belief that is still held by many today. Tanned skin has been shown in the United States to be viewed both as more attractive and more healthy than pale skin. Though sun-tanned skin used to be associated with the sun-exposed manual labor of the lower-class, the associations became dramatically reversed in the mid-20th century, a change usually credited to the trendsetting French woman Coco Chanel making tanned skin seem fashionable, healthy, and luxurious.

Skin tone variability

The tone of human skin can vary from a dark brown to a nearly colorless pigmentation, which may appear reddish due to the blood in the skin. Europeans generally have lighter skin, hair, and eyes than any other group, although this is not always the case. Africans generally have darker skin, hair, and eyes, although this too is not universal. For practical purposes, such as exposure time for sun tanning, six skin types are distinguished following Fitzpatrick (1975), listed in order of decreasing lightness:

type	also called	tanning behavior	von Luschan scale
I	very light, "Celtic" type.	Often burns, occasionally tans.	1-5
II	light, or light-skinned European.	Usually burns, sometimes tans.	6-10
III	light intermediate, or dark-skinned	Rarely burns, usually tans.	11-15

	European.		
IV	dark intermediate, also "Mediterranean" or "olive skin".	Rarely burns, often tans.	16-21
V	dark or "brown" type.	Naturally brown skin, sometimes darkens.	22-28
VI	very dark, or "black" type.	Naturally black-brown skin.	29-36

Geographic variation



Map of indigenous skin color distribution in the world based on Von Luschan's chromatic scale.

Approximately 10% of the variance in skin color occurs within groups, and ~90% occurs between groups. Because skin color has been under strong selective pressure, similar skin colors can result from convergent adaptation rather than from genetic relatedness, populations with similar pigmentation may be genetically no more similar than other widely separated groups. Furthermore, in some parts of the world in which people from different regions have mixed extensively, the connection between skin color and ancestry has been substantially weakened. In Brazil, for example, skin color is not closely associated with the percentage of recent African ancestors a person has, as estimated from an analysis of genetic variants differing in frequency among continent groups.

Considerable speculation has surrounded the possible adaptive value of other physical features characteristic of groups, such as the constellation of facial features observed in many eastern and northeastern Asians. However, any given physical characteristic generally is found in multiple groups, and demonstrating that environmental selective pressures shaped specific physical features will be difficult, since such features may have resulted from sexual selection for individuals with certain appearances or from genetic drift.

Chapter- 11

Human Genetic Clustering

Human genetic clustering data can be used to infer population structure and assign individuals to groups that often correspond with their self-identified geographical ancestry. In 2004, Lynn Jorde and Steven Wooding argued that "Analysis of many loci now yields reasonably accurate estimates of genetic similarity among individuals, rather than populations. Clustering of individuals is correlated with geographic origin or ancestry."

Studies



Gene clusters from Rosenberg (2006) for K=7 clusters. (Cluster analysis divides a dataset into any prespecified number of clusters.) Individuals have genes from multiple clusters.

The cluster prevalent only among the Kalash people (yellow) only splits off at K=7 and greater.



Human population structure can be inferred from multilocus DNA sequence data (Rosenberg et al. 2002, 2005). Individuals from 52 populations were examined at 993 DNA markers. This data was used to partitioned individuals into K = 2, 3, 4, 5, or 6 gene clusters. In this figure, the average fractional membership of individuals from each population is represented by horizontal bars partitioned into K colored segments.

A study by Neil Risch in 2005 used 326 microsatellite markers and self-identified race/ethnic group (SIRE), white (European American), African-American (black), Asian and Hispanic (individuals involved in the study had to choose from one of these categories), to representing discrete "populations", and showed distinct and non-overlapping clustering of the white, African-American and Asian samples. The results

were claimed to confirm the integrity of self-described ancestry: "We have shown a nearly perfect correspondence between genetic cluster and SIRE for major ethnic groups living in the United States, with a discrepancy rate of only 0.14%." But also warned that: "This observation does not eliminate the potential for confounding in these populations. First, there may be subgroups within the larger population group that are too small to detect by cluster analysis. Second, there may not be discrete subgrouping but continuous ancestral variation that could lead to stratification bias. For example, African Americans have a continuous range of European ancestry that would not be detected by cluster analysis but could strongly confound genetic case-control studies.

Studies such as those by Risch and Rosenberg use a computer program called STRUCTURE to find human populations (gene clusters). It is a statistical program that works by placing individuals into one of two clusters based on their overall genetic similarity, many possible pairs of clusters are tested per individual to generate multiple clusters. These populations are based on multiple genetic markers that are often shared between different human populations even over large geographic ranges. The notion of a genetic cluster is that people within the cluster share on average similar allele frequencies to each other than to those in other clusters. In a test of idealised populations, the computer programme STRUCTURE was found to consistently under-estimate the numbers of populations in the data set when high migration rates between populations and slow mutation rates (such as single-nucleotide polymorphisms) were considered.

Nevertheless the Rosenberg *et al.* (2002) paper shows that individuals can be assigned to specific clusters to a high degree of accuracy. One of the underlying questions regarding the distribution of human genetic diversity is related to the degree to which genes are shared between the observed clusters. It has been observed repeatedly that the majority of variation observed in the global human population is found within populations. This variation is usually calculated using Sewall Wright's Fixation index (F_{ST}), which is an estimate of between to within group variation. The degree of human genetic variation is a little different depending upon the gene type studied, but in general it is common to claim that ~85% of genetic variation is found within groups, ~6–10% between groups within the same continent and ~6–10% is found between continental groups. For example The Human Genome Project states "two random individuals from any one group are almost as different [genetically] as any two random individuals from the entire world."

On the other hand Edwards (2003) claims in his essay "Lewontin's Fallacy" that: "It is not true, as *Nature* claimed, that 'two random individuals from any one group are almost as different as any two random individuals from the entire world'" and Risch *et al.* (2002) state "Two Caucasians are more similar to each other genetically than a Caucasian and an Asian." It should be noted that these statements are not the same. Risch *et al.* simply state that two indigenous individuals from the same geographical region are more similar to each other than either is to an indigenous individual from a different geographical region, a claim few would argue with. Jorde et al. put it like this:

The picture that begins to emerge from this and other analyses of human genetic variation is that variation tends to be geographically structured, such that most individuals from the

same geographic region will be more similar to one another than to individuals from a distant region.

Whereas Edwards claims that it is not true that the differences between individuals from different geographical regions represent only a small proportion of the variation within the human population (he claims that within group differences between individuals are not almost as large as between group differences). Bamshad *et al.* (2004) used the data from Rosenberg *et al.* (2002) to investigate the extent of genetic differences between individuals within continental groups relative to genetic differences between individuals between continental groups. They found that though these individuals could be classified very accurately to continental clusters, there was a significant degree of genetic overlap on the individual level, to the extent that, using 377 loci, individual Europeans were about 38% of the time more genetically similar to East Asians than to other Europeans.

The results obtained by clustering analyses are dependent on several criteria:

- The clusters produced are relative clusters and not absolute clusters, each cluster is the product of comparisons between sets of data derived for the study, results are therefore highly influenced by sampling strategies. (Edwards, 2003)
- The geographic distribution of the populations sampled, because human genetic diversity is marked by isolation by distance, populations from geographically distant regions will form much more discrete clusters than those from geographically close regions. (Kittles and Weiss, 2003)
- The number of genes used. The more genes used in a study the greater the resolution produced and therefore the greater number of clusters that will be identified. (Tang, 2005)



Distribution of European clusters identified by Bauchet. When two clusters are identified there is a north-southeast cline that may be due to demic diffusion during the European Neolithic

Additionally two studies of European population clusters have been produced. Seldin *et al.* (2006) identified three European clusters using 5,700 genome-wide polymorphisms. Bauchet *et al.* (2007) used 10,000 polymorphisms to identify five distinct clusters in the European population, consisting of a south-eastern European cluster (including samples from Italians, Armenian, Ashkenazi Jewish and Greek "populations"); a northern-European Cluster (including samples from German, eastern English, Polish and western Irish "populations"); a Basque cluster (including samples from Basque "populations"); a Finnish cluster (including samples from Finnish "populations") and a Spanish cluster (including samples from Spanish "populations"). Most "populations" contained individuals from clusters other than the dominant cluster for that population, there were also individuals with membership of several clusters. The results of this study are presented on a map of Europe. (Bauchet, 2007)

The existence of allelic clines and the observation that the bulk of human variation is continuously distributed, has led some scientists to conclude that any categorization schema attempting to partition that variation meaningfully will necessarily create artificial truncations. (Kittles & Weiss 2003). It is for this reason, Reanne Frank argues, that attempts to allocate individuals into ancestry groupings based on genetic information

have yielded varying results that are highly dependent on methodological design. Serre and Pääbo (2004) make a similar claim:

The absence of strong continental clustering in the human gene pool is of practical importance. It has recently been claimed that “the greatest genetic structure that exists in the human population occurs at the racial level” (Risch et al. 2002). Our results show that this is not the case, and we see no reason to assume that “races” represent any units of relevance for understanding human genetic history.

In a response to Serre and Pääbo (2004), Rosenberg *et al.* (2005) make three relevant observations. Firstly they maintain that their clustering analysis is robust. Secondly they agree with Serre and Pääbo that membership of multiple clusters can be interpreted as evidence for clinality (isolation by distance), though they also comment that this may also be due to admixture between neighbouring groups (small island model). Thirdly they comment that evidence of clusterdness is not evidence for any concepts of "biological race".

Similarly Witherspoon *et al.* (2007) have shown that while it is possible to classify people into genetic clusters this does not resolve the observation that any two individuals from different populations are often genetically more similar to each other than to two individuals from the same population:

Discussions of genetic differences between major human populations have long been dominated by two facts: (a) Such differences account for only a small fraction of variance in allele frequencies, but nonetheless (b) multilocus statistics assign most individuals to the correct population. This is widely understood to reflect the increased discriminatory power of multilocus statistics. Yet Bamshad et al. (2004) showed, using multilocus statistics and nearly 400 polymorphic loci, that (c) pairs of individuals from different populations are often more similar than pairs from the same population. If multilocus statistics are so powerful, then how are we to understand this finding?
All three of the claims listed above appear in disputes over the significance of human population variation and "race"...The Human Genome Project (2001, p. 812) states that "two random individuals from any one group are almost as different [genetically] as any two random individuals from the entire world."

Risch *et al.* (2002) state that "two Caucasians are more similar to each other genetically than a Caucasian and an Asian", but Bamshad *et al.* (2004) used the same data set as Rosenberg *et al.* (2002) to show that Europeans are more similar to Asians 38% of the time than they are to other Europeans when only 377 microsatellite markers are analysed.



If a landmass is considered with variation distributed in one dimension (west-east). Top: Distribution of genetic variation if a small island model is considered; there are two "populations" with a narrow region of hybridisation where migration occurs. This pattern is "clustered".
Bottom: Distribution of genetic variation if isolation by distance is considered; all variation is gradual over the extent of the landmass. This pattern is "clinal".

Percentage similarity between two individuals from different clusters when 377 microsatellite markers are considered.

x	Africans	Europeans	Asians
Europeans	36.5	—	—
Asians	35.5	38.3	—
Indigenous Americans	26.1	33.4	35

In agreement with the observation of Bamshad *et al.* (2004), Witherspoon *et al.* (2007) have shown that many more than 326 or 377 microsatellite loci are required in order to show that individuals are always more similar to individuals in their own population group than to individuals in different population groups, even for three distinct populations.

In 2007 Witherspoon *et al.* sought to investigate these apparently contradictory observations. In their paper *Genetic similarities within and between human populations* they expand upon the observation of Bamshad *et al.* (2004). They show that the observed clustering of human populations into relatively discrete groups is a product of using what they call "population trait values". This means that each individual is compared to the

"typical" trait for several populations, and assigned to a population based on the individual's overall similarity to one of the populations as a whole: "population membership is treated as an additive quantitative genetic trait controlled by many loci of equal effect, and individuals are divided into populations on the basis of their trait values." They therefore claim that clustering analyses cannot necessarily be used to make inferences regarding the similarity or dissimilarity of individuals between or within clusters, but only for similarities or dissimilarities of individuals to the "trait values" of any given cluster. The paper measures the rate of misclassification using these "trait values" and calls this the "population trait value misclassification rate" (C_T). The paper investigates the similarities between individuals by use of what they term the "dissimilarity fraction" (ω): "the probability that a pair of individuals randomly chosen from different populations is genetically more similar than an independent pair chosen from any single population." Witherspoon *et al.* show that two individuals can be more genetically similar to each other than to the typical genetic type of their own respective populations, and yet be correctly assigned to their respective populations. An important observation is that the likelihood that two individuals from different populations will be more similar to each other genetically than two individuals from the same population depends on several criteria, most importantly the number of genes studied and the distinctiveness of the populations under investigation.

Given 10 loci, three distinct populations, and the full spectrum of polymorphisms, the answer is $\omega \sim 0.3$, or nearly one-third of the time. With 100 loci, the answer is ~20% of the time and even using 1000 loci, $\omega \sim 10\%$. However, if genetic similarity is measured over many thousands of loci, the answer becomes *never* when individuals are sampled from geographically separated populations.

By geographically separated populations, they mean sampling of people only from distant geographical regions while omitting intermediate regions, in this case Europe, sub-Saharan Africa, and East Asian. They continue:

On the other hand, if the entire world population were analyzed, the inclusion of many closely related and admixed populations would increase ω... In a similar vein, Romualdi *et al.* (2002) and Serre and Paabo (2004) have suggested that highly accurate classification of individuals from continuously sampled (and therefore closely related) populations may be impossible.... Classification methods typically make use of aggregate properties of populations, not just properties of individuals or even of pairs of individuals... The Structure classification algorithm (Pritchard et al. 2000) also relies on aggregate properties of populations, such as Hardy–Weinberg and linkage equilibrium. In contrast, the pairwise distances used to compute ω make no use of population-level information and are strongly affected by the high level of within-groups variation typical of human populations. This accounts for the difference in behavior between ω and the classification results.

Witherspoon *et al.* also add:

given enough genetic data, individuals can be correctly assigned to their populations of origin is compatible with the observation that most human genetic variation is found within populations, not between them. It is also compatible with our finding that, even when the most distinct populations are considered and hundreds of loci are used, individuals are frequently more similar to members of other populations than to members of their own population.

Chapter- 12

Genetic Disorder

Genetic disorder	
MeSH	D030342

A **genetic disorder** is an illness caused by abnormalities in genes or chromosomes. While some diseases, such as cancer, are due in part to genetic disorders, they can also be caused by environmental factors. Most disorders are quite rare and affect one person in every several thousands or millions. Some types of recessive gene disorders confer an advantage in the heterozygous state in certain environments.

Single gene disorder

Prevalence of some single gene disorders

Disorder	Prevalence (approximate)
Autosomal dominant	
Familial hypercholesterolemia	1 in 500
Polycystic kidney disease	1 in 1250
Hereditary spherocytosis	1 in 5,000
Marfan syndrome	1 in 4,000
Huntington disease	1 in 15,000
Autosomal recessive	
Sickle cell anemia	1 in 625 (African Americans)
Cystic fibrosis	1 in 2,000 (Caucasians)
Tay-Sachs disease	1 in 3,000 (American Jews)
Phenylketonuria	1 in 12,000
Mucopolysaccharidoses	1 in 25,000
Glycogen storage diseases	1 in 50,000
Galactosemia	1 in 57,000

X-linked	
Duchenne muscular dystrophy	1 in 7,000
Hemophilia	1 in 10,000

Values are for liveborn infants

A **single gene disorder** is the result of a single mutated gene. There are estimated to be over 4000 human diseases caused by single gene defects. Single gene disorders can be passed on to subsequent generations in several ways. Genomic imprinting and uniparental disomy, however, may affect inheritance patterns. The divisions between recessive and dominant types are not "hard and fast" although the divisions between autosomal and X-linked types are (since the latter types are distinguished purely based on the chromosomal location of the gene). For example, achondroplasia is typically considered a dominant disorder, but children with two genes for achondroplasia have a severe skeletal disorder that achondroplasics could be viewed as carriers of. Sickle-cell anemia is also considered a recessive condition, but heterozygous carriers have increased resistance to malaria in early childhood, which could be described as a related dominant condition. When a couple where one partner or both are sufferers or carriers of a single gene disorder and wish to have a child they can do so through IVF which means they can then have PGD (pre-implantation genetic diagnosis) to check whether the fertilised egg has had the genetic disorder passed on.

Autosomal dominant

Only one mutated copy of the gene will be necessary for a person to be affected by an autosomal dominant disorder. Each affected person usually has one affected parent. There is a 50% chance that a child will inherit the mutated gene. Conditions that are autosomal dominant sometimes have reduced penetrance, which means that although only one mutated copy is needed, not all individuals who inherit that mutation go on to develop the disease. Examples of this type of disorder are Huntington's disease, neurofibromatosis type 1, Marfan syndrome, hereditary nonpolyposis colorectal cancer, and hereditary multiple exostoses, which is a highly penetrant autosomal dominant disorder. Birth defects are also called congenital anomalies.

Autosomal recessive

Two copies of the gene must be mutated for a person to be affected by an autosomal recessive disorder. An affected person usually has unaffected parents who each carry a single copy of the mutated gene (and are referred to as carriers). Two unaffected people who each carry one copy of the mutated gene have a 25% chance with each pregnancy of having a child affected by the disorder. Examples of this type of disorder are cystic fibrosis, sickle-cell disease, Tay-Sachs disease, Niemann-Pick disease, spinal muscular atrophy, and Roberts syndrome. Certain other phenotypes, such as wet versus dry earwax, are also determined in an autosomal recessive fashion.

X-linked dominant

X-linked dominant disorders are caused by mutations in genes on the X chromosome. Only a few disorders have this inheritance pattern, with a prime example being X-linked hypophosphatemic rickets. Males and females are both affected in these disorders, with males typically being more severely affected than females. Some X-linked dominant conditions such as Rett syndrome, incontinentia pigmenti type 2 and Aicardi syndrome are usually fatal in males either in utero or shortly after birth, and are therefore predominantly seen in females. Exceptions to this finding are extremely rare cases in which boys with Klinefelter syndrome (47,XXY) also inherit an X-linked dominant condition and exhibit symptoms more similar to those of a female in terms of disease severity. The chance of passing on an X-linked dominant disorder differs between men and women. The sons of a man with an X-linked dominant disorder will all be unaffected (since they receive their father's Y chromosome), and his daughters will all inherit the condition. A woman with an X-linked dominant disorder has a 50% chance of having an affected fetus with each pregnancy, although it should be noted that in cases such as incontinentia pigmenti only female offspring are generally viable. In addition, although these conditions do not alter fertility per se, individuals with Rett syndrome or Aicardi syndrome rarely reproduce.

X-linked recessive

X-linked recessive conditions are also caused by mutations in genes on the X chromosome. Males are more frequently affected than females, and the chance of passing on the disorder differs between men and women. The sons of a man with an X-linked recessive disorder will not be affected, and his daughters will carry one copy of the mutated gene. A woman who is a carrier of an X-linked recessive disorder (X^RX^r) has a 50% chance of having sons who are affected and a 50% chance of having daughters who carry one copy of the mutated gene and are therefore carriers. X-linked recessive conditions include the serious diseases Hemophilia A, Duchenne muscular dystrophy, and Lesch-Nyhan syndrome as well as common and less serious conditions such as male pattern baldness and red-green color blindness. X-linked recessive conditions can sometimes manifest in females due to skewed X-inactivation or monosomy X (Turner syndrome).

Y-linked

Y-linked disorders are caused by mutations on the Y chromosome. Because males inherit a Y chromosome from their fathers, *every* son of an affected father will be affected. Because females inherit an X chromosome from their fathers, female offspring of affected fathers are *never* affected.

Since the Y chromosome is relatively small and contains very few genes, there are relatively few Y-linked disorders. Often the symptoms include infertility, which may be circumvented with the help of some fertility treatments. Examples are male infertility and hypertrichosis pinnae.

Mitochondrial

This type of inheritance, also known as maternal inheritance, applies to genes in mitochondrial DNA. Because only egg cells contribute mitochondria to the developing embryo, only mothers can pass on mitochondrial conditions to their children. An example of this type of disorder is Leber's hereditary optic neuropathy.

Multifactorial and polygenic (complex) disorders

Genetic disorders may also be complex, multifactorial, or polygenic, meaning that they are likely associated with the effects of multiple genes in combination with lifestyle and environmental factors. Multifactorial disorders include heart disease and diabetes. Although complex disorders often cluster in families, they do not have a clear-cut pattern of inheritance. This makes it difficult to determine a person's risk of inheriting or passing on these disorders. Complex disorders are also difficult to study and treat because the specific factors that cause most of these disorders have not yet been identified.

On a pedigree, polygenic diseases do tend to "run in families", but the inheritance does not fit simple patterns as with Mendelian diseases. But this does not mean that the genes cannot eventually be located and studied. There is also a strong environmental component to many of them (e.g., blood pressure).

- asthma
- autoimmune diseases such as multiple sclerosis
- cancers
- ciliopathies
- cleft palate
- diabetes
- heart disease
- hypertension
- inflammatory bowel disease
- mental retardation
- mood disorder
- obesity
- refractive error
- infertility

Prognosis and treatment of genetic disorders

Genetic disorders rarely have effective treatments, though gene therapy is being tested as a possible treatment for some genetic diseases, including some forms of retinitis pigmentosa

- Gauchers disease is a genetic disease affecting metabolism. It is more treatable then most other genetic diseases, and can be treated with enzyme replacement therapy, medication miglustat, and bone marrow transplantion.

Chapter- 13

Turner Syndrome

Turner Syndrome



Girl with Turner syndrome before and immediately after her operation for neck-webbing which is a characteristic clinical feature of patients with the syndrome

ICD-10	Q96.
ICD-9	758.6
DiseasesDB	13461
MedlinePlus	000379
eMedicine	ped/2330
MeSH	D014424

Turner syndrome or **Ullrich-Turner syndrome** (also known as "Gonadal dysgenesis") encompasses several conditions, of which monosomy X (absence of an entire sex chromosome, the Barr body) is most common. It is a chromosomal abnormality in which all or part of one of the sex chromosomes is absent (unaffected humans have 46 chromosomes, of which two are sex chromosomes). Typical females have two X chromosomes, but in Turner syndrome, one of those sex chromosomes is missing or has other abnormalities. In some cases, the chromosome is missing in some cells but not others, a condition referred to as mosaicism or 'Turner mosaicism'.

Occurring in 1 in 2000 – 1 in 5000 phenotypic females, the syndrome manifests itself in a number of ways. There are characteristic physical abnormalities, such as short stature, swelling, broad chest, low hairline, low-set ears, and webbed necks. Girls with Turner syndrome typically experience gonadal dysfunction (non-working ovaries), which results in amenorrhea (absence of menstrual cycle) and sterility. Concurrent health concerns are also frequently present, including congenital heart disease, hypothyroidism (reduced hormone secretion by the thyroid), diabetes, vision problems, hearing concerns, and many autoimmune diseases. Finally, a specific pattern of cognitive deficits is often observed, with particular difficulties in visuospatial, mathematical, and memory areas.

Turner's syndrome is named after Henry H. Turner.

Signs and symptoms



Lymphedema, puffy legs of a newborn with Turner syndrome

Common symptoms of Turner syndrome include:

- Short stature
- Lymphedema (swelling) of the hands and feet
- Broad chest (*shield chest*) and widely spaced nipples
- Low hairline
- Low-set ears
- Reproductive sterility
- Rudimentary ovaries gonadal streak (underdeveloped gonadal structures)
- Amenorrhoea, or the absence of a menstrual period

- Increased weight, obesity
- Shield shaped thorax of heart
- Shortened metacarpal IV
- Small fingernails
- Characteristic facial features
- Webbed neck from cystic hygroma in infancy
- Coarctation of the aorta
- Bicuspid aortic valve
- Poor breast development
- Horseshoe kidney
- Visual impairments sclera, cornea, glaucoma, etc.
- Ear infections and hearing loss
- High waist-to-hip ratio (the hips are not much bigger than the waist)
- Attention Deficit/Hyperactivity Disorder (problems with concentration, memory and attention)
- Nonverbal Learning Disability (problems with math, social skills and spatial relations)

Other symptoms may include a small lower jaw (micrognathia), cubitus valgus (turned-in elbows), soft upturned nails, palmar crease, and drooping eyelids. Less common are pigmented moles, hearing loss, and a high-arch palate (narrow maxilla). Turner syndrome manifests itself differently in each female affected by the condition, and no two individuals will share the same symptoms.

Cause

Risk factors for Turner syndrome are not well known. Genetic mosaicism (46XX/45XO) is most often implicated, alongside nondisjunction (45XO) and partial monosomy (46XX). Nondisjunctions increase with maternal age, such as for Down syndrome, but that effect is not clear for Turner syndrome. It is also unknown if there is a genetic predisposition present that causes the abnormality, though most researchers and doctors treating Turners women agree that this is highly unlikely. In 75% of cases inactivated X chromosome is paternal origin. There is currently no known cause for Turner syndrome, though there are several theories surrounding the subject. The only solid fact that is known today is that during conception part or all of the second sex chromosome is not transferred to the fetus. In other words, these females do not have Barr bodies, which are those X chromosomes inactivated by the cell.

Diagnosis



45,X karyotype, showing an unpaired X at the lower right

Turner syndrome may be diagnosed by amniocentesis during pregnancy. Sometimes, fetuses with Turner syndrome are identified by abnormal ultrasound findings (i.e. heart defect, kidney abnormality, cystic hygroma, ascites). Although the recurrence risk is not increased, genetic counseling is often recommended for families who have had a pregnancy or child with Turner syndrome.

A test, called a karyotype or a chromosome analysis, analyzes the chromosomal composition of the individual. This is the test of choice to diagnose Turner syndrome.

Prognosis

While most of the physical findings are harmless, there can be significant medical problems associated with the syndrome.

Cardiovascular

Price et al. (1986 study of 156 female patients with Turner syndrome) showed a significantly greater number of deaths from diseases of the circulatory system than expected, half of them due to congenital heart defects—mostly preductal coarctation of the aorta. When patients with congenital heart disease were omitted from the sample of the study, the mortality from circulatory disorders was not significantly increased.

Cardiovascular malformations are a serious concern as it is the most common cause of death in adults with Turner syndrome. It takes an important part in the 3-fold increase in overall mortality and the reduced life expectancy (up to 13 years) associated with Turner syndrome.

Cause

According to Sybert, 1998 the data are inadequate to allow conclusions about phenotype-karyotype correlations in regard to cardiovascular malformations in Turner syndrome because the number of individuals studied within the less common karyotype groups is too small. Other studies also suggest the presence of hidden mosaicisms that are not diagnosed on usual karyotypic analyses in some patients with 45,X karyotype.

In conclusion, the associations between karyotype and phenotypic characteristics, including cardiovascular malformations, remain questionable.

Prevalence of cardiovascular malformations

The prevalence of cardiovascular malformations among patients with Turner syndrome ranges from 17% (Landin-Wilhelmsen et al., 2001) to 45% (Dawson-Falk et al., 1992).

The variations found in the different studies are mainly attributable to variations in non-invasive methods used for screening and the types of lesions that they can characterize (Ho et al., 2004). However Sybert, 1998 suggests that it could be simply attributable to the small number of subjects in most studies.

Different karyotypes may have differing prevalence of cardiovascular malformations. Two studies found a prevalence of cardiovascular malformations of 30% and 38% in a group of pure 45,X monosomy. But considering other karyotype groups, they reported a prevalence of 24.3% and 11% in patients with mosaic X monosomy, and a prevalence of 11% in patients with X chromosomal structural abnormalities.

The higher prevalence in the group of pure 45,X monosomy is primarily due to a significant difference in the prevalence of aortic valve abnormalities and coarctation of the aorta, the two most common cardiovascular malformations.

Congenital heart disease

The most commonly observed are congenital obstructive lesions of the left side of the heart, leading to reduced flow on this side of the heart. This includes bicuspid aortic valve and coarctation (narrowing) of the aorta. Sybert, 1998 found that more than 50% of the cardiovascular malformations observed in her study of individuals with Turner syndrome were bicuspid aortic valves or coarctation of the aorta, alone or in combination.

Other congenital cardiovascular malformations, such as partial anomalous venous drainage and aortic valve stenosis or aortic regurgitation, are also more common in

Turner syndrome than in the general population. Hypoplastic left heart syndrome represents the most severe reduction in left-sided structures

Bicuspid aortic valve

Up to 15% of adults with Turner syndrome have bicuspid aortic valves, meaning that there are only two, instead of three, parts to the valves in the main blood vessel leading from the heart. Since bicuspid valves are capable of regulating blood flow properly, this condition may go undetected without regular screening. However, bicuspid valves are more likely to deteriorate and later fail. Calcification also occurs in the valves, which may lead to a progressive valvular dysfunction as evidenced by aortic stenosis or regurgitation.

With a prevalence from 12.5% to 17.5% (Dawson-Falk et al., 1992), bicuspid aortic valve is the most common congenital malformation affecting the heart in this syndrome. It is usually isolated but it may be seen in combination with other anomalies, particularly coarctation of the aorta.

Coarctation of the aorta

Between 5% and 10% of those born with Turner syndrome have coarctation of the aorta, a congenital narrowing of the descending aorta, usually just distal to the origin of the left subclavian artery (the artery that branches off the arch of the aorta to the left arm) and opposite to the duct (and so termed "juxtaductal"). Estimates of the prevalence of this malformation in patients with Turner syndrome ranges from 6.9% to 12.5% (Dawson-Falk et al., 1992). A coarctation of the aorta in a female is suggestive of Turner syndrome, and suggests the need for further tests, such as a karyotype.

Partial anomalous venous drainage

This abnormality is a relatively rare congenital heart disease in the general population. The prevalence of this abnormality also is low (around 2.9%) in Turner syndrome. However, its relative risk is 320 in comparison with the general population. Strangely, Turner syndrome seems to be associated with unusual forms of partial anomalous venous drainage.

In the management of a patient with Turner syndrome it is essential to keep in mind that these left-sided cardiovascular malformations in Turner syndrome result in an increased susceptibility to bacterial endocarditis. Therefore prophylactic antibiotics should be considered when procedures with high risk endocarditis are performed, such as dental cleaning.

Turner syndrome is often associated with persistent hypertension, sometimes in childhood. In the majority of Turner syndrome patients with hypertension, there is no specific cause. In the remainder, it is usually associated with cardiovascular or kidney abnormalities, including coarctation of the aorta.

Aortic dilation, dissection, and rupture

Two studies have suggested aortic dilatation in Turner syndrome, typically involving the root of the ascending aorta and occasionally extending through the aortic arch to the descending aorta, or at the site of previous coarctation of the aorta repair.

- Allen et al., 1986 who evaluated 28 girls with Turner syndrome, found a significantly greater mean aortic root diameter in patients with Turner syndrome than in the control group (matched for body surface area). Nonetheless, the aortic root diameter found in Turner syndrome patients were still well within the limits.
- This has been confirmed by the study of Dawson-Falk et al., 1992 who evaluated 40 patients with Turner syndrome. They presented basically the same findings: a greater mean aortic root diameter, which nevertheless remains within the normal range for body surface area.

Sybert, 1998 points out that it remains unproven that aortic root diameters that are relatively large for body surface area but still well within normal limits imply a risk for progressive dilatation.

Prevalence of aortic abnormalities

The prevalence of aortic root dilatation ranges from 8.8% to 42% in patients with Turner syndrome. Even if not every aortic root dilatation necessarily goes on to an aortic dissection (circumferential or transverse tear of the intima), complications such as dissection, aortic rupture resulting in death may occur. The natural history of aortic root dilatation is still unknown, but it is a fact that it is linked to aortic dissection and rupture, which has a high mortality rate.

Aortic dissection affects 1% to 2% of patients with Turner syndrome. As a result any aortic root dilatation should be seriously taken into account as it could become a fatal aortic dissection. Routine surveillance is highly recommended.

Risk factors for aortic rupture

It is well established that cardiovascular malformations (typically bicuspid aortic valve, coarctation of the aorta and some other left-sided cardiac malformations) and hypertension predispose to aortic dilatation and dissection in the general population. At the same time it has been shown that these risk factors are common in Turner syndrome. Indeed these same risk factors are found in more than 90% of patients with Turner syndrome who develop aortic dilatation. Only a small number of patients (around 10%) have no apparent predisposing risk factors. It is important to note that the risk of hypertension is increased 3-fold in patients with Turner syndrome. Because of its relation to aortic dissection blood pressure needs to be regularly monitored and hypertension should be treated aggressively with an aim to keep blood pressure below 140/80 mmHg. It has to be noted that as with the other cardiovascular malformations, complications of aortic dilatation is commonly associated with 45,X karyotype.

Pathogenesis of aortic dissection and rupture

The exact role that all these risk factors play in the process leading to such fatal complications is still quite unclear. Aortic root dilatation is thought to be due to a mesenchymal defect as pathological evidence of cystic medial necrosis has been found by several studies. The association between a similar defect and aortic dilatation is well established in such conditions such as Marfan syndrome. Also, abnormalities in other mesenchymal tissues (bone matrix and lymphatic vessels) suggests a similar primary mesenchymal defect in patients with Turner syndrome. However there is no evidence to suggest that patients with Turner syndrome have a significantly higher risk of aortic dilatation and dissection in absence of predisposing factors. So the risk of aortic dissection in Turner syndrome appears to be a consequence of structural cardiovascular malformations and hemodynamic risk factors rather than a reflection of an inherent abnormality in connective tissue (Sybert, 1998). The natural history of aortic root dilatation is unknown, but because of its lethal potential, this aortic abnormality needs to be carefully followed.

Pregnancy

Turner syndrome is characterized by primary amenorrhea, premature ovarian failure, streak gonads and infertility. However, today's technology (especially with oocyte donation) provide the opportunity of pregnancy in these patients.

As more women with Turner syndrome complete pregnancy thanks to the new modern techniques to treat infertility, it has to be noted that pregnancy may be a risk of cardiovascular complications for the mother. Indeed several studies had suggested an increased risk for aortic dissection in pregnancy. Three deaths have even been reported. The influence of estrogen has been examined but remains unclear. It seems that the high risk of aortic dissection during pregnancy in women with Turner syndrome may be due to the increased hemodynamic load rather than the high estrogen rate. Of course these findings are important and need to be remembered while following a pregnant patient with Turner syndrome.

Cardiovascular malformations in Turner syndrome are also very serious, not only because of their high prevalence in that particular population but mainly because of their high lethal potential and their great implication in the increased mortality found in patients with Turner syndrome. Congenital heart disease needs to be explored in every female newly diagnosed with Turner syndrome. As adults are concerned close surveillance of blood pressure is needed to avoid a high risk of fatal complications due to aortic dissection and rupture.

Skeletal

Normal skeletal development is inhibited due to a large variety of factors, mostly hormonal. The average height of a woman with Turner syndrome, in the absence of

growth hormone treatment, is 4 ft 7 in (140 cm). Patients with Turner's mosaicism can reach normal average height.

The fourth metacarpal bone (fourth toe and ring finger) may be unusually short, as may the fifth.

Due to inadequate production of estrogen, many of those with Turner syndrome develop osteoporosis. This can decrease height further, as well as exacerbate the curvature of the spine, possibly leading to scoliosis. It is also associated with an increased risk of bone fractures.

Kidney

Approximately one-third of all women with Turner syndrome have one of three kidney abnormalities:

1. A single, horseshoe-shaped kidney on one side of the body.
2. An abnormal urine-collecting system.
3. Poor blood flow to the kidneys.

Some of these conditions can be corrected surgically. Even with these abnormalities, the kidneys of most women with Turner syndrome function normally. However, as noted above, kidney problems may be associated with hypertension.

Thyroid

Approximately one-third of all women with Turner syndrome have a thyroid disorder. Usually it is hypothyroidism, specifically Hashimoto's thyroiditis. If detected, it can be easily treated with thyroid hormone supplements.

Diabetes

Women with Turner syndrome are at a moderately increased risk of developing type 1 diabetes in childhood and a substantially increased risk of developing type 2 diabetes by adult years. The risk of developing type 2 diabetes can be substantially reduced by maintaining a normal weight.

Cognitive

Turner syndrome does not typically cause mental retardation or impair cognition. However, learning difficulties are common among women with Turner syndrome, particularly a specific difficulty in perceiving spatial relationships, such as nonverbal learning disorder. This may also manifest itself as a difficulty with motor control or with mathematics. While it is non-correctable, in most cases it does not cause difficulty in daily living. Most Turner Syndrome patients are employed as adults and lead productive lives.

There is also a rare variety of Turner Syndrome, known as "Ring-X Turner Syndrome", which has an approximate 60 percent association with mental retardation. This variety accounts for approximately 2–4% of all Turner Syndrome cases.

Reproductive

Women with Turner syndrome are almost universally infertile. While some women with Turner syndrome have successfully become pregnant and carried their pregnancies to term, this is very rare and is generally limited to those women whose karyotypes are not 45,X. Even when such pregnancies do occur, there is a higher than average risk of miscarriage or birth defects, including Turner Syndrome or Down Syndrome. Some women with Turner syndrome who are unable to conceive without medical intervention may be able to use IVF or other fertility treatments.

Usually estrogen replacement therapy is used to spur growth of secondary sexual characteristics at the time when puberty should onset. While very few women with Turner Syndrome menstruate spontaneously, estrogen therapy requires a regular shedding of the uterine lining ("withdrawal bleeding") to prevent its overgrowth. Withdrawal bleeding can be induced monthly, like menstruation, or less often, usually every three months, if the patient desires. Estrogen therapy does not make a woman with nonfunctional ovaries fertile, but it plays an important role in assisted reproduction; the health of the uterus must be maintained with estrogen if an eligible woman with Turner Syndrome wishes to use IVF (using donated oocytes).

Turner syndrome is a cause of primary amenorrhea, premature ovarian failure (hypergonadotropic hypogonadism), streak gonads and infertility. Failure to develop secondary sex characteristics (sexual infantilism) is typical.

Especially in mosaic cases of Turner syndrome that contains Y chromosome (e.g. 45,X0/46,XY) due to the risk of development of ovarian malignancy (most common is gonadoblastoma) gonadectomy is recommended.

Treatment

As a chromosomal condition, there is no cure for Turner syndrome. However, much can be done to minimize the symptoms. For example:

- Growth hormone, either alone or with a low dose of androgen, will increase growth and probably final adult height. Growth hormone is approved by the U.S. Food and Drug Administration for treatment of Turner syndrome and is covered by many insurance plans. There is evidence that this is effective, even in toddlers.

- Estrogen replacement therapy has been used since the condition was described in 1938 to promote development of secondary sexual characteristics. Estrogens are crucial for maintaining good bone integrity and tissue health. Women with Turner

Syndrome who do not have spontaneous puberty and who are not treated with estrogen are at high risk for osteoporosis.

- Modern reproductive technologies have also been used to help women with Turner syndrome become pregnant if they desire. For example, a donor egg can be used to create an embryo, which is carried by the Turner syndrome woman.

- Uterine maturity is positively associated with years of estrogen use, history of spontaneous menarche, and negatively associated with the lack of current hormone replacement therapy.

Epidemiology

Approximately 99 percent of all fetuses with Turner syndrome result in spontaneous termination during the first trimester. Turner syndrome accounts for about 10 percent of the total number of spontaneous abortions in the United States. The incidence of Turner syndrome in live female births is believed to be around 1 in 2000.

History

The syndrome is named after Henry Hubert Turner, an endocrinologist from Illinois, who described it in 1938. In Europe, it is often called **Ullrich-Turner syndrome** or even **Bonnevie-Ullrich-Turner syndrome** to acknowledge that earlier cases had also been described by European doctors. The first published report of a female with a 45,X karyotype was in 1959 by Dr. Charles Ford and colleagues in Harwell, Oxfordshire and Guy's Hospital in London. It was found in a 14-year-old girl with signs of Turner syndrome.

Chapter- 14

Klinefelter's Syndrome and Cri Du Chat

Klinefelter's syndrome

Klinefelter's syndrome


47,XXY

ICD-10	Q98.0-Q98.4
ICD-9	758.7
eMedicine	ped/1252
MeSH	D007713

Klinefelter syndrome, 47, XXY, or **XXY syndrome** is a condition in which human males have an extra X chromosome. While females have an XX chromosomal makeup, and males an XY, affected individuals have at least two X chromosomes and at least one

Y chromosome. Because of the extra chromosome, individuals with the condition are usually referred to as "XXY Males", or "47, XXY Males".

In humans, Klinefelter syndrome is the most common sex chromosome disorder in males and the second most common condition caused by the presence of extra chromosomes. The condition exists in roughly 1 out of every 1,000 males. One in every 500 males has an extra X chromosome but does not have the syndrome. Other mammals also have the XXY syndrome, including mice.

The principal effects are development of small testicles and reduced fertility. A variety of other physical and behavioral differences and problems are common, though severity varies and many boys and men with the condition have few detectable symptoms.

The syndrome was named after Dr. Harry Klinefelter, who in 1942 worked with Fuller Albright at Massachusetts General Hospital in Boston, Massachusetts and first described it in the same year.

Signs and symptoms



Patient with typical untreated (surgery/hormones) Klinefelter 46,XY/47,XXY mosaic, diagnosed at age 19. Scar from biopsy may be visible on left nipple.



Same patient from the side

Affected males are almost always effectively infertile, although advanced reproductive assistance is sometimes possible. Some degree of language learning impairment may be present, and neuropsychological testing often reveals deficits in executive functions. In adults, possible characteristics vary widely and include little to no signs of affectedness, a lanky, youthful build and facial appearance, or a rounded body type with some degree of gynecomastia (increased breast tissue). Gynecomastia is present to some extent in about a third of affected individuals, a slightly higher percentage than in the XY population. About 10% of XXY males have gynecomastia noticeable enough that they may choose to have cosmetic surgery.

The term *hypogonadism* in XXY symptoms is often misinterpreted to mean "small testicles" or "small penis". In fact, it means decreased testicular hormone/endocrine function. Because of this (primary) hypogonadism, individuals will often have a low

serum testosterone level but high serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels. Despite this misunderstanding of the term, however, it is true that XXY men also have microorchidism (i.e. small testicles).

The more severe end of the spectrum of symptom expression is also associated with an increased risk of germ cell tumors, male breast cancer, and osteoporosis, risks shared to varying degrees with females. Additionally, medical literature shows some individual case studies of Klinefelter syndrome coexisting with other disorders, such as pulmonary disease, varicose veins, diabetes mellitus, and rheumatoid arthritis, but possible correlations between Klinefelter and these other conditions are not well characterized or understood.

In contrast to these potentially increased risks, it is currently thought that rare X-linked recessive conditions occur less frequently in XXY males than in normal XY males, since these conditions are transmitted by genes on the X chromosome, and people with two X chromosomes are typically only carriers rather than affected by these X-linked recessive conditions.

There are many variances within the XXY population, just as in the most common 46,XY population. While it is possible to characterise 47,XXY males with certain body types, that in itself should not be the method of identification as to whether or not someone has 47,XXY. The only reliable method of identification is karyotype testing.

Diagnosis

A karyotype is used to confirm the diagnosis. In this procedure, a small blood sample is drawn. White blood cells are then separated from the sample, mixed with tissue culture medium, incubated, and checked for chromosomal abnormalities, such as an extra X chromosome.

Diagnosis can also be made prenatally via chorionic villus sampling or amniocentesis, tests in which fetal tissue is extracted and the fetal DNA is examined for genetic abnormalities. A 2002 literature review of elective abortion rates found that approximately 50% of pregnancies in the United States with a diagnosis of Klinefelter syndrome were terminated.

Cause

The extra X chromosome is retained because of a nondisjunction event during meiosis (sex cell division). The XXY chromosome arrangement is one of the most common genetic variations from the XY karyotype, occurring in about 1 in 500 live male births.

In mammals with more than one X chromosome, the genes on all but one X chromosome are not expressed; this is known as X inactivation. This happens in XXY males as well as normal XX females. However, in XXY males, a few genes located in the pseudoautosomal regions of their X chromosomes, have corresponding genes on their Y

chromosome and are capable of being expressed. These triploid genes in XXY males may be responsible for symptoms associated with Klinefelter syndrome.

The first published report of a man with a 47,XXY karyotype was by Patricia A. Jacobs and Dr. J.A. Strong at Western General Hospital in Edinburgh, Scotland in 1959. This karyotype was found in a 24-year-old man who had signs of Klinefelter syndrome. Dr. Jacobs described her discovery of this first reported human or mammalian chromosome aneuploidy in her 1981 William Allan Memorial Award address.

Variations

The 48, XXYY (male) syndrome occurs in 1 in 18,000–40,000 births and has traditionally been considered to be a variation of Klinefelter syndrome. XXYY tetrasomy is no longer generally considered a variation of KS, although it has not yet been assigned an ICD-10 code.

Males with Klinefelter syndrome may have a mosaic 47,XXY/46,XY constitutional karyotype and varying degrees of spermatogenic failure. Mosaicism 47,XXY/46,XX with clinical features suggestive of Klinefelter syndrome is very rare. Thus far, only about 10 cases have been described in literature.

Treatment

The genetic variation is irreversible. Testosterone treatment is an option for some individuals who desire a more masculine appearance and identity. Often individuals that have noticeable breast tissue or hypogonadism experience depression and/or social anxiety because they are outside of social norms. This is academically referred to as psychosocial morbidity. At least one study indicates that planned and timed support should be provided for young men with Klinefelter syndrome to ameliorate current poor psychosocial outcomes.

By 2010 over 100 successful pregnancies have been reported using IVF technology with surgically removed sperm material from men with Klinefelter syndrome.

Cri du chat

Cri du chat or Cri-du-chat



Facial features of a patient with Cri du Chat syndrome at age of 8 months (A), 2 years (B), 4 years (C) and 9 years (D)

ICD-10	Q93.4
ICD-9	758.31
OMIM	123450
DiseasesDB	29133
MedlinePlus	001593
eMedicine	ped/504

Cri du chat syndrome, also known as **chromosome 5p deletion syndrome**, **5p minus syndrome** or **Lejeune's syndrome**, is a rare genetic disorder due to a missing part of chromosome 5. Its name is a French term (*cat-cry* or *call of the cat*) referring to the characteristic cat-like cry of affected children. It was first described by Jérôme Lejeune in 1963. The condition affects an estimated 1 in 50,000 live births, strikes all ethnicities, and is more common in females by a 4:3 ratio.

Signs and symptoms

The syndrome gets its name from the characteristic cry of affected infants, which is similar to that of a meowing kitten, due to problems with the larynx and nervous system. About 1/3 of children lose the cry by age 2. Other symptoms of cri du chat syndrome may include:

- feeding problems because of difficulty swallowing and sucking.
- low birth weight and poor growth.
- severe cognitive, speech, and motor delays.
- behavioral problems such as hyperactivity, aggression, tantrums, and repetitive movements.
- unusual facial features which may change over time.
- excessive drooling.
- constipation.

Other common findings include hypotonia, microcephaly, growth retardation, a round face with full cheeks, hypertelorism, epicanthal folds, down-slanting palpebral fissures, strabismus, flat nasal bridge, down-turned mouth, micrognathia, low-set ears, short fingers, single palmar creases, and cardiac defects (eg, ventricular septal defect [VSD], atrial septal defect [ASD], patent ductus arteriosus [PDA], tetralogy of Fallot). People with Cri du chat are fertile and can reproduce.

Less frequently encountered findings include cleft lip and palate, preauricular tags and fistulas, thymic dysplasia, intestinal malrotation, megacolon, inguinal hernia, dislocated hips, cryptorchidism, hypospadias, rare renal malformations (eg, horseshoe kidneys, renal ectopia or agenesis, hydronephrosis), clinodactyly of the fifth fingers, talipes equinovarus, pes planus, syndactyly of the second and third fingers and toes, oligosyndactyly, and hyperextensible joints. The syndrome may also include various dermatoglyphics, including transverse flexion creases, distal axial triradius, increased whorls and arches on digits, and a single palmar crease.

Late childhood and adolescence findings include significant intellectual

disability, microcephaly, coarsening of facial features, prominent supraorbital ridges, deep-set eyes, hypoplastic nasal bridge, severe malocclusion, and scoliosis.

Affected females reach puberty, develop secondary sex characteristics, and menstruate at the usual time. The genital tract is usually normal in females except for a report of a

bicornuate uterus. In males, testes are often small, but spermatogenesis is thought to be normal.

Genetics

Cri du chat syndrome is due to a partial deletion of the short arm of chromosome number 5, also called "5p monosomy". Approximately 90% of cases results from a sporadic, or randomly-occurring, *de novo* deletion. The remaining 10-15% are due to unequal segregation of a parental balanced translocation where the 5p monosomy is often accompanied by a trisomic portion of the genome. These individuals may have more severe disease than those with isolated monosomy of 5p.

Most cases involve total loss of the most distant 20-10% of the material on the short arm. Fewer than 10% of cases have other rare cytogenetic aberrations (eg, interstitial deletions, mosaicisms, rings and de novo translocations). The deleted chromosome 5 is paternal in origin in about 80% of *de novo* cases.

Loss of a small region in band 5p15.2 (cri du chat critical region) correlates with all the clinical features of the syndrome with the exception of the catlike cry, which maps to band 5p15.3 (catlike critical region). The results suggest that 2 noncontiguous critical regions contain genes involved in this condition's etiology. Two genes in these regions, Semaphorine F (SEMA5A) and delta catenin (CTNND2), are potentially involved in cerebral development. The deletion of the telomerase reverse transcriptase (hTERT) gene localized in 5p15.33 may contribute to the phenotypic changes in cri du chat syndrome as well.

Diagnosis and Management

Diagnosis is based on the distinctive cry and accompanying physical problems. Genetic counseling and genetic testing may be offered to families with individuals who have cri du chat syndrome. Children may be treated by speech, sound, and occupational therapists. Cardiac abnormalities often require surgical correction.

Chapter- 15

Huntington's Disease

Huntington's disease



A microscope image of Medium spiny neurons (yellow) with nuclear inclusions (orange), which occur as part of the disease process, image width 360 µm

ICD-10	G10., F02.2
ICD-9	333.4, 294.1
OMIM	143100
DiseasesDB	6060
MedlinePlus	000770
eMedicine	article/1150165 article/792600 article/289706
MeSH	D006816

Huntington's disease, **chorea**, or **disorder** (**HD**), is a neurodegenerative genetic disorder that affects muscle coordination and leads to cognitive decline and dementia. It typically becomes noticeable in middle age. HD is the most common genetic cause of abnormal involuntary writhing movements called chorea and is much more common in people of Western European descent than in those from Asia or Africa. The disease is caused by an autosomal dominant mutation on either of an individual's two copies of a gene called Huntingtin, which means any child of an affected parent has a 50% risk of inheriting the disease. In rare situations where both parents have an affected copy this risk increases to 75%, and when either parent has two affected copies, the risk is 100% (all children will be affected). Physical symptoms of Huntington's disease can begin at any age from infancy to old age, but usually begin between 35 and 44 years of age. About 6% of cases start before the age of 21 years with an akinetic-rigid syndrome; they progress faster and vary slightly. The variant is classified as **juvenile**, **akinetic-rigid** or **Westphal variant HD**.

The Huntingtin gene normally provides the genetic information for a protein that is also called "Huntingtin". The mutation of the Huntingtin gene codes for a different form of the protein, whose presence results in gradual damage to specific areas of the brain. The exact way this happens is not fully understood. Genetic testing can be performed at any stage of development, even before the onset of symptoms. This raises several ethical debates regarding the age at which an individual is considered mature enough to choose testing, the right of parents to test their children, and confidentiality and disclosure of test results. Genetic counseling has developed to inform and aid individuals considering genetic testing and has become a model for other genetically dominant diseases.

Symptoms of the disease can vary between individuals and even members of the same family, but the symptoms progress predictably for most individuals. The earliest symptoms are a general lack of coordination and an unsteady gait. As the disease advances, uncoordinated, jerky body movements become more apparent, along with a decline in mental abilities and behavioral and psychiatric problems. Physical abilities are gradually impeded until coordinated movement becomes very difficult, and mental abilities generally decline into dementia. Complications such as pneumonia, heart

disease, and physical injury from falls reduce life expectancy to around twenty years after symptoms begin. There is no cure for HD, and full-time care is required in the later stages of the disease, but there are emerging treatments to relieve some of its symptoms.

Self-help support organizations, first founded in the 1960s and increasing in number, have been working to increase public awareness, to provide support for individuals and their families, and to promote research. The Hereditary Disease Foundation, a research group born out of the first support organization, was instrumental in finding the gene in 1993. Since that time there have been important discoveries every few years and understanding of the disease is improving. Current research directions include determining the exact mechanism of the disease, improving animal models to expedite research, clinical trials of pharmaceuticals to treat symptoms or slow the progression of the disease, and studying procedures such as stem cell therapy with the goal of repairing damage caused by the disease.

Signs and symptoms

Symptoms of Huntington's disease commonly become noticeable between the ages of 35 and 44 years, but they can begin at any age from infancy to old age. In the early stages, there are subtle changes in personality, cognition, and physical skills. The physical symptoms are usually the first to be noticed, as cognitive and psychiatric symptoms are generally not severe enough to be recognized on their own at the earlier stages. Almost everyone with Huntington's disease eventually exhibits similar physical symptoms, but the onset, progression and extent of cognitive and psychiatric symptoms vary significantly between individuals.

The most characteristic initial physical symptoms are jerky, random, and uncontrollable movements called chorea. Chorea may be initially exhibited as general restlessness, small unintentionally initiated or uncompleted motions, lack of coordination, or slowed saccadic eye movements. These minor motor abnormalities usually precede more obvious signs of motor dysfunction by at least three years. The clear appearance of symptoms such as rigidity, writhing motions or abnormal posturing appear as the disorder progresses. These are signs that the system in the brain that is responsible for movement is affected. Psychomotor functions become increasingly impaired, such that any action that requires muscle control is affected. Common consequences are physical instability, abnormal facial expression, and difficulties chewing, swallowing and speaking. Eating difficulties commonly cause weight loss and may lead to malnutrition. Sleep disturbances are also associated symptoms. Juvenile HD differs from these symptoms in that it generally progresses faster and chorea is exhibited briefly, if at all, with rigidity being the dominant symptom. Seizures are also a common symptom of this form of HD.

Reported prevalences of behavioral and psychiatric symptoms in Huntington's disease

Irritability	38–73%
Apathy	34–76%
Anxiety	34–61%

Depressed mood	33–69%
Obsessive and compulsive	10–52%
Psychotic	3–11%

Cognitive abilities are impaired progressively. Especially affected are executive functions which include planning, cognitive flexibility, abstract thinking, rule acquisition, initiating appropriate actions and inhibiting inappropriate actions. As the disease progresses, memory deficits tend to appear. Reported impairments range from short-term memory deficits to long-term memory difficulties, including deficits in episodic (memory of one's life), procedural (memory of the body of how to perform an activity) and working memory. Cognitive problems tend to worsen over time, ultimately leading to dementia. This pattern of deficits has been called a subcortical dementia syndrome to distinguish it from the typical effects of cortical dementias e.g. Alzheimer's disease.

Reported neuropsychiatric manifestations are anxiety, depression, a reduced display of emotions (blunted affect), egocentrism, aggression, and compulsive behavior, the latter of which can cause or worsen addictions, including alcoholism, gambling, and hypersexuality. Difficulties in recognizing other people's negative expressions have also been observed. Prevalence of these symptoms is also highly variable between studies, with estimated rates for lifetime prevalence of psychiatric disorders between 33% and 76%. For many sufferers and their families these symptoms are among the most distressing aspects of the disease, often affecting daily functioning and constituting reason for institutionalisation. Suicidal thoughts and suicide attempts are more common than in the general population.

Mutant Huntingtin is expressed throughout the body and associated with abnormalities in peripheral tissues that are directly caused by such expression outside the brain. These abnormalities include muscle atrophy, cardiac failure, impaired glucose tolerance, weight loss, osteoporosis and testicular atrophy.

Genetics

All humans have the Huntingtin gene (*HTT*), which codes for the protein Huntingtin (Htt). Part of this gene is a repeated section called a trinucleotide repeat, which varies in length between individuals and may change length between generations. When the length of this repeated section reaches a certain threshold, it produces an altered form of the protein, called mutant Huntingtin protein (mHtt). The differing functions of these proteins are the cause of pathological changes which in turn cause the disease symptoms. The Huntington's disease mutation is genetically dominant and almost fully penetrant: mutation of either of a person's *HTT* genes causes the disease. It is not inherited according to sex, but the length of the repeated section of the gene, and hence its severity, can be influenced by the sex of the affected parent.

Genetic mutation

HD is one of several trinucleotide repeat disorders which are caused by the length of a repeated section of a gene exceeding a normal range. The *HTT* gene is located on the short arm of chromosome 4 at 4p16.3. *HTT* contains a sequence of three DNA bases—cytosine-adenine-guanine (CAG)—repeated multiple times (i.e. ... CAGCAGCAG ...), known as a trinucleotide repeat. CAG is the genetic code for the amino acid glutamine, so a series of them results in the production of a chain of glutamine known as a polyglutamine tract (or polyQ tract), and the repeated part of the gene, the *PolyQ region*.

Classification of the trinucleotide repeat, and resulting disease status, depends on the number of CAG repeats

Repeat count	Classification	Disease status
<28	Normal	Unaffected
28–35	Intermediate	Unaffected
36–40	Reduced Penetrance	+/- Affected
>40	Full Penetrance	Affected

Generally, people have fewer than 36 repeated glutamines in the polyQ region which results in production of the cytoplasmic protein Huntingtin. However, a sequence of 36 or more glutamines results in the production of a protein which has different characteristics. This altered form, called mHtt (mutant Htt), increases the decay rate of certain types of neuron. Regions of the brain have differing amounts and reliance on these type of neurons, and are affected accordingly. Generally, the number of CAG repeats is related to how much this process is affected, and accounts for about 60% of the variation of the age of the onset of symptoms. The remaining variation is attributed to environment and other genes that modify the mechanism of HD. 36–40 repeats result in a reduced-penetrance form of the disease, with a much later onset and slower progression of symptoms. In some cases the onset may be so late that symptoms are never noticed. With very large repeat counts, HD has full penetrance and can occur under the age of 20, when it is then referred to as juvenile HD, akinetic-rigid, or Westphal variant HD. This accounts for about 7% of HD carriers.

Inheritance



Huntington's disease is inherited in an autosomal dominant fashion. The probability of each offspring inheriting an affected gene is 50%. Inheritance is independent of gender, and the gene does not skip generations.

Huntington's disease has autosomal dominant inheritance, meaning that an affected individual typically inherits one copy of the gene with an expanded trinucleotide repeat (the mutant allele) from an affected parent. Since penetrance of the mutation is very high those who have a mutated copy of the gene will have the disease. In this type of inheritance pattern, each offspring of an affected individual has a 50% risk of inheriting the mutant allele and therefore being affected with the disorder (see figure). This probability is sex-independent.

Trinucleotide CAG repeats over 28 are unstable during replication and this instability increases with the number of repeats present. This usually leads to new expansions as generations pass (dynamic mutations) instead of reproducing an exact copy of the trinucleotide repeat. This causes the number of repeats to change in successive generations, such that an unaffected parent with an "intermediate" number of repeats (28–35), or "reduced penetrance" (36–40), may pass on a copy of the gene with an increase in the number of repeats that produces fully penetrant HD. Such increases in the number of repeats (and hence earlier age of onset and severity of disease) in successive generations

is known as genetic anticipation. Instability is greater in spermatogenesis than oogenesis; maternally inherited alleles are usually of a similar repeat length, whereas paternally inherited ones have a higher chance of increasing in length. It is rare for Huntington's disease to be caused by a new mutation, where neither parent has over 36 CAG repeats.

Individuals with both genes affected are rare, except in large consanguineous families. For some time HD was thought to be the only disease for which possession of a second mutated gene did not affect symptoms and progression, but it has since been found that it can affect the phenotype and the rate of progression. Offspring of an individual who has two affected genes will inherit one of them and therefore definitely inherit the disease. Offspring where both parents have one affected gene have a 75% risk of inheriting HD, including a 25% risk of inheriting two affected genes. Identical twins, who have inherited the same affected gene, typically have differing ages of onset and symptoms.

Mechanism

The Htt protein interacts with over 100 other proteins, and appears to have multiple biological functions. The behavior of mutated mHtt protein is not completely understood, but it is toxic to certain types of cells, particularly in the brain. Damage mainly occurs in the striatum, but as the disease progresses, other areas of the brain are also significantly affected. As the damage accumulates, symptoms associated with the functions of these brain areas appear. Planning and modulating movement are the main functions of the striatum, and difficulties with these are initial symptoms.

Htt function

Htt is expressed in all mammalian cells. The highest concentrations are found in the brain and testes, with moderate amounts in the liver, heart, and lungs. The function of Htt in humans is unclear. It interacts with proteins which are involved in transcription, cell signaling and intracellular transporting. In animals genetically modified to exhibit HD, several functions of Htt have been found. In these animals, Htt is important for embryonic development, as its absence is related to embryonic death. It also acts as an anti-apoptotic agent preventing programmed cell death and controls the production of brain-derived neurotrophic factor, a protein which protects neurons and regulates their creation during neurogenesis. Htt also facilitates vesicular transport and synaptic transmission and controls neuronal gene transcription. If the expression of Htt is increased and more Htt produced, brain cell survival is improved and the effects of mHtt are reduced, whereas when the expression of Htt is reduced, the resulting characteristics are more typical of the presence of mHtt. In humans the disruption of the normal gene does not cause the disease. It is currently concluded that the disease is not caused by inadequate production of Htt, but by a gain of toxic function of mHtt.

Cellular changes due to mHtt



A microscope image of a neuron with inclusion (stained orange) caused by HD, image width 250 μm

There are multiple cellular changes through which the toxic function of mHtt may manifest and produce the HD pathology. During the biological process of posttranslational modification of mHtt, cleavage of the protein can leave behind shorter fragments constituted of parts of the polyglutamine expansion. The polar nature of glutamine causes interactions with other proteins when it is overabundant in Htt proteins. Thus, the Htt molecule strands will form hydrogen bonds with one another, forming a protein aggregate rather than folding into functional proteins. Over time, the aggregates accumulate, ultimately interfering with neuron function because these fragments can then misfold and coalesce, in a process called protein aggregation, to form inclusion bodies within cells. Neuronal inclusions run indirect interference. The excess protein aggregates clump together at axons and dendrites in neurons which mechanically stops the transmission of neurotransmitters because vesicles (filled with neurotransmitters) can no longer move through the cytoskeleton. Ultimately, over time, less and less neurotransmitters are available for release in signaling other neurons as the neuronal inclusions grow. Inclusion bodies have been found in both the cell nucleus and cytoplasm. Inclusion bodies in cells of the brain are one of the earliest pathological changes, and some experiments have found that they can be toxic for the cell, but other experiments have shown that they may form as part of the body's defense mechanism and help protect cells.

Several pathways by which mHtt may cause cell death have been identified. These include: effects on chaperone proteins, which help fold proteins and remove misfolded ones; interactions with caspases, which play a role in the process of removing cells; the toxic effects of glutamine on nerve cells; impairment of energy production within cells; and effects on the expression of genes. The cytotoxic effects of mHtt are strongly enhanced by interactions with a protein called *Rhes*, which is expressed mainly in the striatum. Rhes was found to induce sumoylation of mHtt, which causes the protein clumps to disaggregate—studies in cell culture showed that the clumps were much less toxic than the disaggregated form.

An additional theory that explains another way cell function may be disrupted by HD proposes that damage to mitochondria in striatal cells (numerous accounts of mitochondrial metabolism deficiency have been found) and the interactions of the altered huntingtin protein with numerous proteins in neurons leads to an increased vulnerability of glutamine, which, in large amounts, has been found to be an excitotoxin. Excitotoxins may cause damage to numerous cellular structures. Although glutamine isn't found in excessively high amounts, its been postulated that because of the increased vulnerability, even normal amounts glutamine can cause excitotoxins to be expressed. Furthermore, the increase in sensitivity turn on capases are activated by the repeat expansion of polyglutamine and the increase in sensitivity. The huntingtin protein is cleaved into tiny pieces by capases; these nuclear aggregates disrupt transcription by interfering with the production of proteins by "slipping" into the nucleus of the neuron. Unfortunately, the cellular stress caused by the interference causes more huntingtin to be broken up until apoptosis occurs.

Macroscopic changes due to mHtt



Area of the brain damaged by Huntington's disease – striatum (shown in purple)

HD affects specific areas of the brain. The most prominent early effects are in a part of the basal ganglia called the neostriatum, which is composed of the caudate nucleus and putamen. Other areas affected include the substantia nigra, layers 3, 5 and 6 of the cerebral cortex, the hippocampus, purkinje cells in the cerebellum, lateral tuberal nuclei of the hypothalamus and parts of the thalamus. These areas are affected according to their structure and the types of neurons they contain, reducing in size as they lose cells. Striatal spiny neurons are the most vulnerable, particularly ones with projections towards the external globus pallidus, with interneurons and spiny cells projecting to the internal pallidum being less affected. HD also causes an abnormal increase in astrocytes.

The basal ganglia—the part of the brain most prominently affected by HD—play a key role in movement and behavior control. Their functions are not fully understood, but current theories propose that they are part of the cognitive executive system and the motor circuit. The basal ganglia ordinarily inhibit a large number of circuits that generate specific movements. To initiate a particular movement, the cerebral cortex sends a signal to the basal ganglia that causes the inhibition to be released. Damage to the basal ganglia can cause the release or reinstatement of the inhibitions to be erratic and uncontrolled, which results in an awkward start to motion or motions to be unintentionally initiated, or a motion to be halted before, or beyond, its intended completion. The accumulating damage to this area causes the characteristic erratic movements associated with HD.

There are two ways the basal ganglia can be damaged: directly and indirectly. In the direct pathway, fewer neurotransmitters are sent the internal globus pallidus (IGP), which in turn comprehends this as a decrease in inhibition, thereby releasing a greater amount of neurotransmitters than normal. The thalamus, which receives a greater number of neurotransmitters, becomes inhibited, thus sending less neurotransmitters to the motor cortex. Ultimately, the motor cortex is understimulated and movements are slower than usual. The indirect pathway starts with the external globus pallidus receiving a lower number of neurotransmitters, and in turn, responding to this decrease as a signal of less inhibition, releases more neurotransmitters. The subthalamic nuclei (STN), which receives the signals from the external globus pallidus, releases fewer neurotransmitters to the IGP in response to the increase of neurotransmitters received. The IGP is now considerably inhibited because the job of the STN is to excite the IGP and therefore, the IGP releases fewer neurotransmitters. In this context, the reception of less neurotransmitters by the thalamus is perceived as less inhibition. Finally, the motor cortex receives more neurotransmitters and is overstimulated, causing the jerky movements usual in chorea. Since there are two different types of neurons in the striatum, a different neuron, with different axons and dendrites targeted, is stimulated in each pathway (though neurotransmitter GABA is used in both) and thus both can run at the same time. The indirect pathway is generally affected first, which is why chorea is among the first symptoms, but eventually, both types of neurons die off and movement is severely limited.

Transcriptional dysregulation

CREB-binding protein (CBP), a transcription factor, is essential for cell function because as a coactivator at a significant number of promoters, it activates the transcription of genes for survival pathways. Furthermore, the amino acids that form CBP include a strip 18 glutamines. Thus, the glutamines on CBP interact directly with the increased numbers of glutamine on the Htt chain and CBP gets pulled away from its typical location next to the nucleus. Specifically, CRB contains a acetyltransferase domain that, in an experiment performed by Steffan and colleagues, showed that a Htt exon 1 with 51 glutamines binded to this domain in CBP. Autopsied brains of those who had Huntington's disease also have been found to have incredibly reduced amounts of CBP. Plus, when CBP is overexpressed, polyglutamine-induced death diminished, further demonstrating that CBP plays an important role in Huntington's disease and neurons in general.

Diagnosis

Medical diagnosis of the onset of HD can be made following the appearance of physical symptoms specific to the disease. Genetic testing can be used to confirm a physical diagnosis if there is no family history of HD. Even before the onset of symptoms, genetic testing can confirm if an individual or embryo carries an expanded copy of the trinucleotide repeat in the *HTT* gene that causes the disease. Genetic counseling is available to provide advice and guidance throughout the testing procedure, and on the implications of a confirmed diagnosis. These implications include the impact on an individual's psychology, career, family planning decisions, relatives and relationships.

Despite the availability of pre-symptomatic testing, only 5% of those at risk of inheriting HD choose to do so.

Clinical



Coronal section from a MR brain scan of a patient with HD showing atrophy of the heads of the caudate nuclei, enlargement of the frontal horns of the lateral ventricles, and generalised cortical atrophy.

A physical examination, sometimes combined with a psychological examination, can determine whether the onset of the disease has begun. Excessive unintentional movements of any part of the body are often the reason for seeking medical consultation. If these are abrupt and have random timing and distribution, they suggest a diagnosis of HD. Cognitive or psychiatric symptoms are rarely the first diagnosed; they are usually

only recognized in hindsight or when they develop further. How far the disease has progressed can be measured using the *unified Huntington's disease rating scale* which provides an overall rating system based on motor, behavioral, cognitive, and functional assessments. Medical imaging, such as computerized tomography (CT) and magnetic resonance imaging (MRI), only shows visible cerebral atrophy in the advanced stages of the disease. Functional neuroimaging techniques such as fMRI and PET can show changes in brain activity before the onset of physical symptoms.

Genetic

Because HD is dominant, there is a strong motivation for individuals who are at risk of inheriting it to seek a diagnosis. The genetic test for HD consists of a blood test which counts the numbers of CAG repeats in each of the *HTT* alleles. A positive result is not considered a diagnosis, since it may be obtained decades before the symptoms begin. However, a negative test means that the individual does not carry the expanded copy of the gene and will not develop HD.

A pre-symptomatic test is a life-changing event and a very personal decision. The main reason given for choosing testing for HD is to aid in career and family decisions. Over 95% of individuals at risk of inheriting HD do not proceed with testing, mostly because there is no treatment. A key issue is the anxiety an individual experiences about not knowing whether they will eventually develop HD, compared to the impact of a positive result. Irrespective of the result, stress levels have been found to be lower two years after being tested, but the risk of suicide is increased after a positive test result. Individuals found to have not inherited the disorder may experience survivor guilt with regard to family members who are affected. Other factors taken into account when considering testing include the possibility of discrimination and the implications of a positive result, which usually means a parent has an affected gene and that the individual's siblings will be at risk of inheriting it. Genetic counseling in HD can provide information, advice and support for initial decision-making, and then, if chosen, throughout all stages of the testing process. Counseling and guidelines on the use of genetic testing for HD have become models for other genetic disorders, such as autosomal dominant cerebellar ataxias. Presymptomatic testing for HD has also influenced testing for other illnesses with genetic variants such as polycystic kidney disease, familial Alzheimer's disease and breast cancer.

Embryonic

Embryos produced using in vitro fertilisation may be genetically tested for HD using preimplantation genetic diagnosis. This technique, where a single cell is extracted from a 4 to 8 cell embryo and then tested for the genetic abnormality, can then be used to ensure embryos with affected *HTT* genes are not implanted, and therefore any offspring will not inherit the disease. It is also possible to obtain a prenatal diagnosis for an embryo or fetus in the womb.

Differential diagnosis

About 90% of HD diagnoses based on the typical symptoms and a family history of the disease are confirmed by genetic testing to have the expanded trinucleotide repeat that causes HD. Most of the remaining are called HD-like disorders. Most of these other disorders are collectively labelled HD-like (HDL). The cause of most HDL diseases is unknown, but those with known causes are due to mutations in the prion protein gene (HDL1), the junctophilin 3 gene (HDL2), a recessively inherited *HTT* gene (HDL3—only found in one family and poorly understood), and the gene encoding the TATA box-binding protein (HDL4/SCA17). Other autosomal dominant diseases that can be misdiagnosed as HD are dentatorubral-pallidoluysian atrophy and neuroferritinopathy. There are also autosomal recessive disorders that resemble sporadic cases of HD. Main examples are chorea acanthocytosis, pantothenate kinase-associated neurodegeneration and X-linked McLeod syndrome.

Management



Chemical structure of tetrabenazine, an approved compound for the management of chorea in HD

There is no cure for HD, but there are treatments available to reduce the severity of some of its symptoms. For many of these treatments, comprehensive clinical trials to confirm their effectiveness in treating symptoms of HD specifically are incomplete. As the disease progresses and a person's ability to tend to their own needs reduces, carefully managed multidisciplinary caregiving becomes increasingly necessary.

Tetrabenazine was developed specifically to reduce the severity of chorea in HD, it was approved in 2008 for this use in the US. Other drugs that help to reduce chorea include neuroleptics and benzodiazepines. Compounds such as amantadine or remacemide are still under investigation but have shown preliminary positive results. Hypokinesia and rigidity can be treated with antiparkinsonian drugs, and myoclonic hyperkinesia can be treated with valproic acid.

Psychiatric symptoms can be treated with medications similar to those used in the general population. Selective serotonin reuptake inhibitors and mirtazapine have been recommended for depression, while atypical antipsychotic drugs are recommended for psychosis and behavioural problems.

Weight loss and eating difficulties due to dysphagia and other muscle discoordination are common, making nutrition management increasingly important as the disease advances. Thickening agents can be added to liquids as thicker fluids are easier and safer to swallow. Reminding the patient to eat slowly and to take smaller pieces of food into the mouth may also be of use to prevent choking. If eating becomes too hazardous or uncomfortable, the option of using a percutaneous endoscopic gastrostomy is available. This is a feeding tube, permanently attached through the abdomen into the stomach, which reduces the risk of aspirating food and provides better nutritional management.

Although there have been relatively few studies of exercises and therapies that help rehabilitate cognitive symptoms of HD, there is some evidence for the usefulness of physical therapy, occupational therapy, and speech therapy. However, more rigorous studies are needed for health authorities to endorse them. A multidisciplinary approach may be important to limit disability. The families of individuals, who have inherited or are at risk of inheriting HD, have generations of experience of HD which may be outdated and lack knowledge of recent breakthroughs and improvements in genetic testing, family planning choices, care management, and other considerations. Genetic counseling benefits these individuals by updating their knowledge, dispelling any myths they may have and helping them consider their future options and plans.

Prognosis

The length of the trinucleotide repeat accounts for 60% of the variation in the age of onset and the rate of progression of symptoms. A longer repeat results in an earlier age of onset and a faster progression of symptoms. For example, individuals with a trinucleotide repeat greater than sixty repeats often develop the disease before twenty years of age, and those with less than forty repeats may not develop noticeable symptoms. The remaining variation is due to environmental factors and other genes that influence the mechanism of the disease.

Life expectancy in HD is generally around 20 years following the onset of visible symptoms. Most of the complications that are life-threatening result from muscle coordination issues, or to a lesser extent from behavioural changes resulting from the decline in cognitive function. The largest risk is pneumonia, which is the cause of death of one-third of those with HD. As the ability to synchronise movements deteriorates, difficulty clearing the lungs and an increased risk of aspirating food or drink both increase the risk of contracting pneumonia. The second greatest risk is heart disease, which causes almost a quarter of fatalities of those with HD. Suicide is the next greatest cause of fatalities, with 7.3% of those with HD taking their own lives and up to 27% attempting to do so. It is unclear to what extent suicidal thoughts are influenced by psychiatric symptoms, as they may be considered to be a response of an individual to

retain a sense of control of their life or to avoid the later stages of the disease. Other associated risks include choking, physical injury from falls, and malnutrition.

Epidemiology

The late onset of Huntington's disease means it does not usually affect reproduction. The worldwide prevalence of HD is 5-10 cases per 100,000 persons, but varies greatly geographically as a result of ethnicity, local migration and past immigration patterns. Prevalence is similar for men and women. The rate of occurrence is highest in peoples of Western European descent, averaging around seventy per million people, and is lower in the rest of the world, e.g. one per million people of Asian and African descent. Additionally, some localized areas have a much higher prevalence than their regional average. One of the highest prevalences is in the isolated populations of the Lake Maracaibo region of Venezuela, where HD affects up to seven thousand per million people. Other areas of high localization have been found in Tasmania and specific regions of Scotland, Wales and Sweden. Increased prevalence in some cases occurs due to a local founder effect, a historical migration of carriers into an area of geographic isolation. Some of these carriers have been traced back hundreds of years using genealogical studies. Genetic haplotypes can also give clues for the geographic variations of prevalence.

Until the discovery of a genetic test, statistics could only include clinical diagnosis based on physical symptoms and a family history of HD, excluding those who died of other causes before diagnosis. These cases can now be included in statistics and as the test becomes more widely available, estimates of the prevalence and incidence of the disorder are likely to increase.

History


THE

MEDICAL AND SURGICAL REPORTER.

No. 789.] PHILADELPHIA, APRIL 13, 1872. [Vol. XXVI.—No. 15.

ORIGINAL DEPARTMENT.

Communications.

ON CHOREA.

By George Huntington, M. D.,
Of Pomeroy, Ohio.

Essay read before the Meigs and Mason Academy of Medicine at Middleport, Ohio, February 15, 1872

Chorea is essentially a disease of the nervous system. The name "chorea" is given to the disease on account of the *dancing* propensities of those who are affected by it, and it is a very appropriate designation. The disease, as it is commonly seen, is by no means a dangerous or serious affection, however distressing it may be to the one suffering from it, or to his friends. Its most marked and char-

The upper extremities may be the first affected, or both simultaneously. All the voluntary muscles are liable to be affected, those of the face rarely being exempted.

If the patient attempt to protrude the tongue it is accomplished with a great deal of difficulty and uncertainty. The hands are kept rolling—first the palms upward, and then the backs. The shoulders are shrugged, and the feet and legs kept in perpetual motion; the toes are turned in, and then everted; one foot is thrown across the other, and then suddenly withdrawn, and, in short, every conceivable attitude and expression is assumed, and so varied and irregular are the motions gone through with, that a complete description of



In 1872 George Huntington described the disorder in his first paper "On Chorea" at the age of 22.

The first definite mention of HD was in a letter by Charles Oscar Waters, published in the first edition of Robley Dunglison's *Practice of Medicine* in 1842. Waters described 'a form of chorea, vulgarly called magrums', including accurate descriptions of the chorea, its progression, and the strong heredity of the disease. In 1846 Charles Gorman observed how higher prevalence seemed to occur in localized regions. Independently of Gorman and Waters, both students of Dunglison at Jefferson Medical College, Johan Christian Lund also produced an early description in 1860. He specifically noted that in Setesdalen, a secluded area in Norway, there was a high prevalence of dementia associated with a pattern of jerking movement disorders that ran in families.

The first thorough description of the disease was by George Huntington in 1872. Examining the combined medical history of several generations of a family exhibiting similar symptoms, he realized their conditions must be linked; he presented his detailed and accurate definition of the disease as his first paper. Unknowingly, Huntington described the exact pattern of inheritance of autosomal dominant disease years before the rediscovery of Mendelian inheritance. "Of its hereditary nature. When either or both the parents have shown manifestations of the disease ..., one or more of the offspring almost invariably suffer from the disease ... But if by any chance these children go through life without it, the thread is broken and the grandchildren and great-grandchildren of the original shakers may rest assured that they are free from the disease.". Sir William Osler was interested in the disorder and chorea in general, and was impressed with Huntington's paper, stating that "*In the history of medicine, there are few instances in which a disease has been more accurately, more graphically or more briefly described*." Osler's continued interest in HD, combined with his influence in the field of medicine, helped to rapidly spread awareness and knowledge of the disorder throughout the medical community. Great interest was shown by scientists in Europe, including Louis Théophile Joseph Landouzy, Désiré-Magloire Bourneville, Camillo Golgi, and Joseph Jules Dejerine, and until the end of the century, much of the research into HD was European in origin. By the end of the 19th century, research and reports on HD had been published in many countries and the disease was recognized as a worldwide condition.

During the rediscovery of Mendelian inheritance at the turn of the 20th century, HD was used tentatively as an example of autosomal dominant inheritance. The English biologist William Bateson used the pedigrees of affected families to establish that HD did have an autosomal dominant inheritance pattern. The strong inheritance pattern prompted several researchers to attempt to trace and connect family members of previous studies, one of whom was Smith Ely Jelliffe. Jelliffe collected information from across New York State and published several articles regarding the genealogy of HD in New England. Jelliffe's research roused the interest of his college friend, Charles Davenport, who commissioned Elizabeth Muncey to produce the first field study of families with HD, and construct their pedigrees, on the East Coast of the United States. Davenport used this information to document the variable age of onset and range of symptoms of HD and make the claim that most cases of HD in the USA could be traced back to a handful of individuals. This research was further embellished in 1932 by P. R. Vessie, who popularised the idea that three brothers who left England in 1630, bound for Boston were the progenators of HD in the USA. The claim that the earliest progenators had been established and eugenic bias of

Muncey's, Davenport, and Vessie's work contributed to misunderstandings and prejudice about HD. Muncey and Davenport also popularised the idea that in the past some HD sufferers may have been thought to be possessed by spirits or victims of witchcraft, and were sometimes shunned or exiled by society. This idea has not been proven, and there is evidence to the contrary, for example, the community of the family studied by George Huntington openly accommodated those who exhibited symptoms of HD.

Research into the disorder continued steadily through the 20th century, reaching a major breakthrough in 1983 when the US–Venezuela Huntington's Disease Collaborative Research Project discovered the approximate location of a causal gene. This was the result of an extensive study begun in 1979, focusing on the populations of two isolated Venezuelan villages, Barranquitas and Lagunetas, where there was an unusually high prevalence of the disease. Among other innovations, the project developed DNA marking methods which were an important step in making the Human Genome Project possible. In 1993 the research group isolated the precise causal gene at 4p16.3, making this the first autosomal disease locus found using genetic linkage analysis. In the same time frame, key discoveries concerning the mechanisms of the disorder were being made, including the findings by Anita Harding's research group on the effects of the gene's length.

Modelling the disease in various types of animals, such as the transgenic mouse developed in 1996, enabled larger scale experiments. As these animals have faster metabolisms and much shorter lifespans than humans, results from experiments are received sooner, speeding research. The 1997 discovery that mHtt fragments misfold led to the discovery of the nuclear inclusions they cause. These advances have led to increasingly extensive research into the proteins involved with the disease, potential drug treatments, care methods, and the gene itself.